

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representation of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :

A61K 39/395, C07K 15/14

A1

(11) International Publication Number:

WO 91/06320

(43) International Publication Date:

16 May 1991 (16.05.91)

(21) International Application Number: PCT/US90/06179

(22) International Filing Date: 25 October 1990 (25.10.90)

(30) Priority data:

427,765

27 October 1989 (27.10.89)

US

591,823

2 October 1990 (02.10.90)

US

(71) Applicant: SCRIPPS CLINIC AND RESEARCH FOUNDATION [US/US]; 10666 North Torrey Pines Road, La Jolla, CA 92037 (US).

(72) Inventors: HAITT, Andrew, C. ; 660 Torrance Street, San Diego, CA 92103 (US). HEIN, Mich. B. ; 1355 Santa Margarita Drive, Fallbrook, CA 92028 (US).

(74) Agents: FITTING, Thomas; Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd., 11300 Sorrento Valley Road, #200, San Diego, CA 92121 (US) et al.

(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent).

Published

*With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

(54) Title: COMPOSITIONS CONTAINING PLANT-PRODUCED GLYCOPOLYPEPTIDE MULTIMERS, MULTIMER-IC PROTEINS, AND THEIR USE

(57) Abstract

The present invention contemplates a transgenic plant having somatic and germ cells containing at least two mammalian genes coding for polypeptides capable of autogenously associating with each other to form a biologically active multimer. The present invention also contemplates glycopolypeptide multimers having a polypeptide that contains an immunoglobulin amino acid residue sequence and an oligosaccharide that comprises a core pentasaccharide and N-acetylglucosamine-containing uter branches, such that the multimer is free from sialic acid. The production of passive immunity against a preselected antigen by administering a sialic acid free glycopolypeptide multimer to an animal is also contemplated.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CI	Côte d'Ivoire	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

**COMPOSITIONS CONTAINING
PLANT-PRODUCED GLYCOPOLYPEPTIDE MULTIMERS,
MULTIMERIC PROTEINS, AND THEIR USE**

5

DESCRIPTION

Technical Field

The present invention relates to the expression of foreign multimeric proteins in plants, transgenic plants that express such multimeric proteins, foreign glycopolypeptide multimers produced in plants and uses of plant-produced glycopolypeptide multimers.

Background

It is known that polypeptides can be expressed in a wide variety of cellular hosts. A wide variety of structural genes have been isolated from mammals and viruses, joined to transcriptional and translational initiation and termination regulatory signals from a source other than the structural gene, and introduced into hosts into which these regulatory signals are functional.

For economic reasons it would be desirable to utilize genetically engineered unicellular microorganisms to produce a wide variety of polypeptides. However, because of the inherent differences in the nature of unicellular organisms on one hand and mammalian cells on the other, the folding and processing of polypeptides in unicellular microorganisms appears to be quite different from the folding and processing that is effected in mammalian cells. As a result, mammalian polypeptides derived from unicellular microorganisms are not always properly folded or processed to provide the desired degree of biological or physiological activity in the

obtained polypeptide.

To that end attempts have been made, with varying degrees of success, to express mammalian polypeptides in plants.

5 The first transgenic plants expressing foreign genes were tobacco plants produced by the use of Agrobacterium tumefaciens vectors as described by Horsch et al., Science, 223:496 (1984) and De Block et al., EMBO J., 31:681 (1984). The transgenic plants
10 produced in these studies were resistant to an antibiotic by virtue of the introduced transgene. These first transgenic plants were produced by introducing the foreign genes into plant protoplasts, i.e., plant cells that have had their cell wall
15 removed either by mechanical action or enzymatic digestion. Subsequent transformation methods based on regenerable explants such as leaves, stems and roots have allowed the transformation of several dicotyledonous plant species. A variety of free DNA
20 delivery methods, including microinjection, electroporation and particle gun technologies have allowed the transformation of monocotyledonous plants, such as corn, and rice.

 Expression of a multimeric protein, i.e., a
25 protein constituted by two different polypeptide chains in significant yields has not been achieved. The factors controlling the assembly of such multimeric proteins are not well characterized except that it is known that the individual polypeptide
30 chains must be present in sufficient quantity and in the same subcellular compartment.

 The expression of a multimeric protein in plant cells requires that the genes coding for the polypeptide chains be present in the same plant cell.
35 The probability of actually introducing both genes

into the same cell is extremely remote. Even if such a single cell cotransformant is produced, the plant must then be regenerated from this single-cell cotransformant.

5 Multimeric proteins containing carbohydrate residues, glycopolypeptide multimers, are found in both plants and animals. Both plant and animal glycopolypeptide multimers have a common pentasaccharide core, $\text{Man}\alpha 1-3(\text{Man}\alpha 1-6)\text{Man}\beta 1-4\text{GLcNAc}\beta 1-4\text{GLcNAc}-$, that is directly linked to an asparagine residue present in the polypeptide. See, Kornfeld and Kornfeld, Ann. Rev. Biochem., 54:631 (1985).

10 Plant and animal glycopolypeptide multimers also have outer branches of oligosaccharides directly linked to the common pentasaccharide core. Animal and plant glycopolypeptide outer branches have N-acetylglucosamine in them, while the outer branches present in yeast only contain mannose.

15 Plant and animal glycopolypeptide multimers contain different terminal carbohydrates that are directly linked to the outer branches of the oligosaccharides present. Animal glycopolypeptide multimers including mammalian glycopolypeptide multimers have sialic acid present as a terminal carbohydrate residue, while plant glycopolypeptide multimers do not. See Sturm et al., J. Biol. Chem., 262:13392 (1987).

20 Secretory IgA is a glycopolypeptide multimer made up of two IgA molecules joining chain (J chain) and secretory component. IgA is the major class of antibody found in secretion, such as milk, saliva, tears, respiratory secretions and intestinal secretions.

25 Secretory IgA is resistant to denaturation caused by harsh environments. This denaturation

30

35

assistance requires that the complex secretory IgA molecule containing IgA molecules, J chain and secretory component be accurately and efficiently assembled.

5 It has now been found that multimeric proteins can be expressed in relatively high yields in transgenic plants generated in a particular manner. In addition, the accurate and efficient expression of glycopolyptide multimers free from sialic acid in
10 transgenic plants has been discovered.

It has also been discovered that passive immunity can be produced in an animal by providing sialic acid-containing soluble immunoglobulin containing a variety of different antibodies having
15 varying antigen specificities to that animal. See, Tacket et al., New England J. Med., 318:1240 (1988) and Eibl et al., New England J. Med., 319:1-7 (1988). To date there is no report of producing passive immunity in an animal by administering an encapsulated
20 glycopolyptide multimer capable of binding a preselected pathogen.

A method of producing passive immunity by administering an encapsulated, glycopolyptide multimer that is free from sialic acid and capable of
25 binding a preselected pathogen has been discovered.

Summary of the Invention

The production of biologically or physiologically active multimeric proteins such as
30 abzymes, immunoglobulins, enzymes, and the like, in relatively high yields is achieved in a transgenic, sexually reproducible plant constituted by plant cells that each contain integrated within the nuclear genome plural mammalian genes coding for autogenously linking
35 polypeptides as well as the autogenously linking

polypeptides themselves. These polypeptides are present in the plant cells as a biologically active polypeptide multimer such as a homomultimer or a heteromultimer. These transgenic plants are morphologically normal but for the presence of the mammalian genes is substantially all of their cells. The respective gene products can be present in substantially all or a portion of the plant cells, i.e., the products can be localized to a cell type, tissue or organ.

The foregoing transgenic plants are produced by introducing into the nuclear genome of a first member of the plant species a first mammalian gene that codes for an autogenously linkable monomeric polypeptide which is a constituent part of the multimeric protein to produce a viable first transformant. Similarly, another mammalian gene, coding for another autogenously linkable monomeric polypeptide which also is a constituent part of the multimeric protein is introduced into the nuclear genome of a second member of the same plant species to produce a viable second transformant. The so-obtained first and second transformants are then sexually crossed and cultivated to generate a progeny population from which transgenic plant species that produce the multimeric protein are isolated.

Transgenic plants embodying the present invention are useful not only to produce economically, and in relatively high yields, the desired multimeric protein but also as means for separating and/or concentrating a preselected ligand, such as a metal ion, from a fluid, i.e., gas or liquid.

The transgenic plants produce a glycopolypeptide multimer containing a polypeptide having a glucosylated core portion as well as N-

acetylglucosamin containing outer ranches and an amino acid residue sequence of an immunoglobulin molecul , where the multimer is free from detectable sialic acid residues.

5 Passive immunity against a preselected pathogen is achieved in an animal by administering to the animal an encapsulated, biologically active glycopolypeptide multimer capable of binding a pathogen antigen in an amount sufficient to establish
10 within said animal a prophylactic concentration of the multimer. The glycopolypeptide multimer administered is free from detectable sialic acid residues and contains a polypeptide having a glycosylated core portion as well as N-acetylglucosamine containing
15 outer branches and an amino acid residue sequence of an immunoglobulin molecule.

 The present invention also contemplates biologically active compositions comprising a glycopolypeptide multimer containing a polypeptide
20 having a glycosylated core portion as well as a N-acetylglucosamine containing outer branches and an amino acid residue sequence of an immunoglobulin molecule, where the multimer is free from detectable sialic acid residues and is encapsulated in a
25 protective coating such as a plant cell.

Brief Description of the Drawings

 In the drawings forming a portion of this disclosure:

30 FIGURE 1, a schematic showing the major features of the Kappa chain cDNA, Figure 1A, and the gamma chain cDNA, Figure 1B, from the 6D4 hybridoma are shown. The location of important restriction endonuclease sites are shown. The location of the
35 complementary determining regions, the framework regions and the constant regions are indicated.

In FIGURE 2, a schematic of the pMON530 binary 35 S-NOS cassette vector described in Rogers et al., Meth. In Enzymol., 153:253 (1987) is shown. The CaMV 35 S promoter segment; 3', the NOS 3' nontranslated sequences. Also present are a 1.6-kb segment carrying the pBR322 origin of replication, a 2.4-kb segment of the nopaline-type pTiT37 plasmid that carries the right border of the nopaline T-DNA and intact nopaline synthase (NOS) gene, a 2.2-kb segment of Tn7 carrying the spectinomycin/streptomycin resistance determinant, a 1.6-kb segment encoding a chimeric NOS-NPTII'-NOS gene that provides selectable kanamycin resistance in transformed plant cells, and a synthetic multilinker containing unique restriction sites for insertion of other DNA segments.

In FIGURE 3, a schematic of the stable expression of antibody molecules in a plant by sexually crossing plants containing the individual kappa and gamma chains.

FIGURE 4: In Figure 4A shows a Southern blot of transgenic leaf DNA demonstrating the incorporation of both kappa and gamma genes into the transgenic plant's genome is shown. DNA from a transformant expressing a light chain cDNA without a leader sequence (pHi101) is shown in Lane 1. Lane 2 contains DNA from a cDNA transformant expressing the heavy chain cDNA with no leader (pHi201). Lane 3 contains DNA from a transformant expressing the full length light chain cDNA with a leader (pHi102). Lane 4 contains DNA from a transformant expressing the heavy chain cDNA with a leader (pHi202). Lane 5 contains DNA from an F₁ plant derived from a cross between a plant expressing the full length gamma cDNA and a plant expressing the full length kappa cDNA (pHi102 x pHi201). Figure 4B is a Northern blot of transgenic tobacco leaf RNA demonstrating the expression of kappa

and gamma mRNA in the transgenic plant leaf. Lane 1 contains RNA from a transformant expressing a light chain cDNA without a leader sequence (pHi101). Lane 2 contains RNA from a heavy chain cDNA transformant, no leader (pHi201). Lane 3 contains RNA from a transformant expressing full length light chain with leader (pHi102), lane 4 contains RNA from a transformant expressing heavy chain with leader (pHi202). Lane 5 contains RNA from an F₁ plant derived from a cross between plant expressing full length gamma cDNA and a plant expressing full length kappa cDNA (pHi102 x pHi201). Lanes from separate hybridizations were aligned with respect to the 18S (1900 bp) and 25S (3700 bp) ribosomal RNA bands on the blots as detected by methylene blue staining.

FIGURE 5 shows a Western blot of leaf proteins from transgenic tobacco plants expressing immunoglobulin kappa chains, immunoglobulin gamma chains, or assembled immunoglobulin IgG. In Lanes 1-7 the leaf protein extracts contained dithiothreitol (DTT) and in Lanes 8 and 9 the leaf protein extracts did not contain DTT. Lane 1 contains 100 ng of purified antibody from the 6D4 hybridoma. Lane 2 contains 15 ug of wild type plant extract protein. Lane 3 contains 15 ug of protein from a plant transformed with truncated kappa chain cDNA (pHi101) containing no leader sequence. Lane 4 contains 15 ug of plant extract from a plant transformed with truncated gamma chain cDNA (pHi102). Lane 5 contains 15 ug of plant extract from a full length kappa cDNA transformant (pHi102). Lane 6 contains 15 ug of plant extract from a full length gamma chain cDNA transformant (pHi202). Lane 7 contains 15 ug of plant extract from an F₁ plant derived from a cross between kappa and gamma transformants. Lane 8 contains 100 ng of 6D4 antibody (no DTT); Lane 9 is the same as lane 7

except no DTT is present in the sample. Gamma and kappa on the left refer to the positions of the 6D4 heavy and light chains.

FIGURE 6 illustrates the structures of the major types of asparagine-linked oligosaccharides (N-linked oligosaccharides). The boxed area encloses the pentasaccharide core (glycosylated core portions) common to all N-linked oligosaccharides. The complex and hybrid N-linked oligosaccharides have N-acetylglucosamine containing outer branches, and the high mannose N-linked oligosaccharides do not. The complex, hybrid and high mannose oligosaccharides are shown in Figure 6A, 6B and 6C respectively.

FIGURE 7 illustrates the structure of N-acetyneuraminic acid and other sialic acids as described in Hughes, Glycoproteins, Chapman and Hall, New York, NY (1983).

FIGURE 8 illustrates the location of carbohydrate in human heavy chains as described in Jeske and Capra, in Fundamental Immunology, W.E. Paul, ed., Raven Press, New York, NY (1984). Glucosamine oligosaccharides are represented by vertical bars; shaded if in homologous positions in two or more chains, open if in unique positions. Horizontal striated bars show the positions of galactosamine oligosaccharides. The upper scale gives residue positions for the top five chains; the lower scale gives positions for μ and ϵ chains.

FIGURE 9A illustrates the substrate and Figure 9B illustrates the inhibitor used to demonstrate the 6D4 antibody produced in tobacco plants functions to catalyze the substrate.

FIGURE 10 illustrates the binding of the gamma heavy chain to various lectins. The IgG antibody produced in plants or mice was subjected to SDS-PAGE and then transferred to nitrocellulose according to

the procedure described by Chua, Meth. Enzymol., 69:434-446 (1980) and Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor, NY (1988). Lane 1 contains 1 mg of IgG 6D4 antibody produced in tobacco plants and lane 2 contains 1 mg of IgG, 6D4 antibody isolated from mouse ascites. Lane 3 contains 1 mg each of human transferrin (complex type carbohydrate) as described by Faye and Chrispeels, Anal. Biochem., 149:218-224 (1985). Abbreviations are Con A: Concanavalin A; RCA: Ricinus communis agglutinin; WGA: wheat germ agglutinin; DSA: Datura stramonium agglutinin; PHA: Phaseolus vulgaris erythrolectin; Endo H: endoglycosydase H; α -MG: α -methylglucopyranoside.

Detailed Description of the Invention

A. Definitions

Dicotyledon (dicot): A flowering plant whose embryos have two seed halves or cotyledons. Examples of dicots are: tobacco; tomato; the legumes including alfalfa; oaks; maples; roses; mints; squashes; daisies; walnuts; cacti; violets; and buttercups.

Monocotyledon (monocot): A flowering plant whose embryos have one cotyledon or seed leaf. Examples of monocots are: lilies; grasses; corn; grains, including oats, wheat and barley; orchids; irises; onions and palms.

Lower plant: Any non-flowering plant including ferns, gymnosperms, conifers, horsetails, club mosses, liver warts, hornworts, mosses, red algae, brown algae, gametophytes, sporophytes of pteridophytes, and green algae.

Eukaryotic hybrid vector: A DNA by means of which a DNA coding for polypeptid (insert) can be introduced into a eukaryotic cell.

5 Extrachromosomal ribosomal DNA (rDNA): A DNA found in unicellular eukaryotes outside the chromosomes, carrying one or more genes coding for ribosomal RNA and replicating autonomously (independent of the replication of the chromosomes).

10 Palindromic DNA: A DNA sequence with one or more centers of symmetry.

DNA: Desoxyribonucleic acid.

T-DNA: A segment of transferred DNA.

rDNA: Ribosomal DNA.

RNA: Ribonucleic acid.

15 rRNA: Ribosomal RNA.

Ti-plasmid: Tumor-inducing plasmid.

Ti-DNA: A segment of DNA from Ti-plasmid.

20 Insert: A DNA sequence foreign to the rDNA, consisting of a structural gene and optionally additional DNA sequences.

25 Structural gene: A gene coding for a polypeptide and being equipped with a suitable promoter, termination sequence and optionally other regulatory DNA sequences, and having a correct reading frame.

30 Signal Sequence: A DNA sequence coding for an amino acid sequence attached to the polypeptide which binds the polypeptide to the endoplasmatic reticulum and is essential for protein secretion.

(Selective) Genetic marker: A DNA sequence coding for a phenotypical trait by means of which transformed cells can be selected from untransformed cells.

Promoter: A recognition site on a DNA sequence or group of DNA sequences that provide an expression control element for a gene and to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene.

Inducible promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include light, heat, anaerobic stress, alteration in nutrient conditions, presence or absence of a metabolite, presence of a ligand, microbial attack, wounding and the like.

Viral promoter: A promoter with a DNA sequence substantially similar to the promoter found at the 5' end of a viral gene. A typical viral promoter is found at the 5' end of the gene coding for the p21 protein of MMTV described by Huang et al., Cell, 27:245 (1981). (All references cited in this application are incorporated by reference.)

Synthetic promoter: A promoter that was chemically synthesized rather than biologically derived. Usually synthetic promoters incorporate sequence changes that optimize the efficiency of RNA polymerase initiation.

Constitutive promoter: A promoter where the rate of RNA polymerase binding and initiation is approximately constant and relatively independent of external stimuli. Examples of constitutive promoters include the cauliflower mosaic virus 35S and 19S promoters described by Poszkowski et al., EMBO J., 3:2719 (1989) and Odell et al., Nature, 313:810 (1985).

Temporally regulated promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated at a specific time during

development. Examples of temporally regulated promoters are given in Chua et al., Science, 244:174-181 (1989).

Spatially regulated promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism such as the leaf, stem or root. Examples of spatially regulated promoters are given in Chua et al., Science, 244:174-181 (1989).

Spatiotemporally regulated promoter: A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism at a specific time during development. A typical spatiotemporally regulated promoter is the EPSP synthase-35S promoter described by Chua et al., Science, 244:174-181 (1989).

Single-chain antigen-binding protein: A polypeptide composed of an immunoglobulin light-chain variable region amino acid sequence (V_L) tethered to an immunoglobulin heavy-chain variable region amino acid sequence (V_H) by a peptide that links the carboxyl terminus of the V_L sequence to the amino terminus of the V_H sequence.

Single-chain antigen-binding protein-coding gene: A recombinant gene coding for a single-chain antigen-binding protein.

Multimeric protein: A globular protein containing more than one separate polypeptide or protein chain associated with each other to form a single globular protein. Both heterodimeric and homodimeric proteins are multimeric proteins.

Polypeptide and peptide: A linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.

Protein: A linear series of greater than about 50 amino acid residues connected one to the other as in a polypeptide.

Chelating agent: A chemical compound, peptide or protein capable of binding a metal. Examples of chelating agents include ethylene diamine tetra acetic acid (EDTA), ethyleneglycol-bis-(beta-aminoethyl ether) N, N, N', N'-tetra acetic acid (EGTA), 2,3-dimercaptopropane-1-sulfonic acid (DMPS), and 2,3-dimercaptosuccinic acid (DMSA), and the like.

Metal chelation complex: A complex containing a metal bound to a chelating agent.

Immunoglobulin product: A polypeptide, protein or multimeric protein containing at least the immunologically active portion of an immunoglobulin heavy chain and is thus capable of specifically combining with an antigen. Exemplary immunoglobulin products are an immunoglobulin heavy chain, immunoglobulin molecules, substantially intact immunoglobulin molecules, any portion of an immunoglobulin that contains the paratope, including those portions known in the art as Fab fragments, Fab' fragment, F(ab')₂ fragment and Fv fragment.

Immunoglobulin molecule: A multimeric protein containing the immunologically active portions of an immunoglobulin heavy chain and immunoglobulin light chain covalently coupled together and capable of specifically combining with antigen.

Fab fragment: A multimeric protein consisting of the portion of an immunoglobulin molecule containing the immunologically active portions of an immunoglobulin heavy chain and an immunoglobulin light chain covalently coupled together and capable of specifically combining with antigen.

Fab fragments are typically prepared by proteolytic digestion of substantially intact immunoglobulin molecules with papain using methods that are well known in the art. However, a Fab fragment may also be prepared by expressing in a suitable host cell the desired portions of immunoglobulin heavy chain and immunoglobulin light chain using methods well known in the art.

F_v fragment: A multimeric protein consisting of the immunologically active portions of an immunoglobulin heavy chain variable region and an immunoglobulin light chain variable region covalently coupled together and capable of specifically combining with antigen. F_v fragments are typically prepared by expressing in suitable host cell the desired portions of immunoglobulin heavy chain variable region and immunoglobulin light chain variable region using method well known in the art.

Asexual propagation: Producing progeny by regenerating an entire plant from leaf cuttings, stem cuttings, root cuttings, single plant cells (protoplasts) and callus.

Glycosylated core portion: The pentasaccharide core common to all asparagine-linked oligosaccharides. The pentasaccharide core has the structure Man α 1-3 (man α 1-6) Man β 1-4 6LcNac β 1-4 6LcNac- (ASN amino acid). The pentasaccharide core typically has 2 outer branches linked to the pentasaccharide core.

N-acetylglucosamine containing outer branches: The additional oligosaccharides that are linked to the pentasaccharide core (glycosylated core portion) of asparagine-linked oligosaccharides. The outer branches found on both mammalian and plant glycopolypeptides contain N-acetylglucosamine in

direct contrast with yeast outer branches that only contain mannose. Mammalian outer branches have sialic acid residues linked directly to the terminal portion of the outer branch.

5 Glycopolyptide multimer: A globular protein containing a glycosylated polypeptide or protein chain and at least one other polypeptide or protein chain bonded to each other to form a single globular protein. Both heterodimeric and homodimeric
10 glycoproteins are multimeric proteins. Glycosylated polypeptides and proteins are n-glycans in which the C(1) of N-acetylglucosamine is linked to the amide group of asparagine.

Immunoglobulin superfamily molecule: A
15 molecule that has a domain size and amino acid residue sequence that is significantly similar to immunoglobulin or immunoglobulin related domains. The significance of similarity is determined statistically using a computer program such as the Align program
20 described by Dayhoff et al., Meth Enzymol., 91:524-545 (1983). A typical Align score of less than 3 indicates that the molecule being tested is a member of the immunoglobulin gene superfamily.

 The immunoglobulin gene superfamily contains
25 several major classes of molecules including those shown in Table A and described by Williams and Barclay, in Immunoglobulin Genes, p361, Academic Press, New York, NY (1989).

Table A

The Known Members of Th Immunoglobulin Gene
Superfamily*

5	<u>Immunoglobulin</u>
	Heavy chains (IgM)
	Light chain kappa
	Light chain lambda
	<u>T cell receptor (Tcr) complex</u>
10	Tcr α -chain
	Tcr β chain
	Tcr gamma chain
	Tcr X-chain
	CD3 gamma chain
15	CD3 δ -chain
	CD3 ϵ -chain
	<u>Major histocompatibility complex (MHC) antigens</u>
	Class I H-chain
	β_2 -microglobulin
20	Class II α
	Class II β
	<u>β_2-m associated antigens</u>
	TL H chain
	Qa-2 H chain
25	CD1a H chain
	<u>T lymphocyte antigens</u>
	CD2
	CD4
	CD7
30	CD8 chain I
	CD8 Chain II δ
	CD28
	CTLA4

Haemopoietic/endothelium antigens

LFA-3

MRC OX-45

Brain/lymphoid antigens

5 Thy-1

MRC OX-2

Immunoglobulin receptors

Poly Ig R

Fc gamma 2b/gamma 1R

10 FcεRI(α)

Neural molecules

Neural adhesion molecule (MCAM)

Myelin associated gp (MAG)

P₀ myelin protein15 Tumor antigen

Carcinembryonic antigen (CEA)

Growth factor receptors

Platelet-derived growth factor (PDGF) receptor

Colony stimulating factor-1 (CSF1) receptor

20 Non-cell surface moleculesα₁ B-glycoprotein

Basement membrane link protein

25 * See Williams and Barclay, in Immunoglobulin Genes, p361, Academic Press, NY (1989); and Sequences of Proteins of Immunological Interest, 4th ed., U.S. Dept. of Health and Human Services (1987).

30 Catalytic site: The portion of a molecule that is capable of binding a reactant and improving the rate of a reaction. Catalytic sites may be present on polypeptides or proteins, enzymes, organics, organo-metal compounds, metals and the like.

35 A catalytic site may be made up of separate portions

present on one or more polypeptide chains or compounds. These separate catalytic portions associate together to form a larger portion of a catalytic site. A catalytic site may be formed by a polypeptide or protein that is bonded to a metal.

Enzymatic site: The portion of a protein molecule that contains a catalytic site. Most enzymatic sites exhibit a very high selective substrate specificity. An enzymatic site may be comprised of two or more enzymatic site portions present on different segments of the same polypeptide chain. These enzymatic site portions are associated together to form a greater portion of an enzymatic site. A portion of an enzymatic site may also be a metal.

Self-pollination: The transfer of pollen from male flower parts to female flower parts on the same plant. This process typically produces seed.

Cross-pollination: The transfer of pollen from the male flower parts of one plant to the female flower parts of another plant. This process typically produces seed from which viable progeny can be grown.

Epitope: A portion of a molecule that is specifically recognized by an immunoglobulin product. It is also referred to as the determinant or antigenic determinant.

Abzyme: An immunoglobulin molecule capable of acting as an enzyme or a catalyst.

Enzyme: A protein, polypeptide, peptide RNA molecule, or multimeric protein capable of accelerating or producing by catalytic action some change in a substrate for which it is often specific.

B. Methods of Producing Transgenic Plants
Containing A Multimeric Protein

The present invention provides a novel method for producing a plant containing a multimeric protein comprised of first and second polypeptides. Generally, the method combines the following elements:

1. Inserting into the genome of a first member of a plant species a gene coding for a first polypeptide to produce a first transformant.

2. Inserting into the genome of a second member of a plant species a gene coding for a second polypeptide to produce a second transformant.

3. Producing a population of progeny from the first and second transformants.

4. Isolating from the population, a progeny having the multimeric protein.

A plant produced by the present invention contains a multimeric protein comprised of a first and second polypeptides associated together in such a way as to assume a biologically functional conformation. In one embodiment of this invention, the multimeric protein is a ligand binding polypeptide (receptor) that forms a ligand binding site which specifically binds to a preselected ligand to form a complex having a sufficiently strong binding between the ligand and the ligand binding site for the complex to be isolated. In another embodiment, the multimeric protein is an immunoglobulin molecule comprised of an immunoglobulin heavy chain and an immunoglobulin light chain. The immunoglobulin heavy and light chains are associated with each other and assume a conformation having an antigen binding site specific for, as evidenced by its ability to be competitively inhibited, a preselected or predetermined antigen. When the multimeric protein is an antigen binding

protein its affinity or avidity is generally greater than 10^5 M^{-1} or usually greater than 10^6 M^{-1} , and preferably greater than 10^8 M^{-1} .

5 In a further embodiment, the multimeric protein is a Fab fragment consisting of a portion of an immunoglobulin heavy chain and a portion of an immunoglobulin light chain. The immunoglobulin heavy and light chains are associated with each other and assume a conformation having an antigen binding site
10 specific for a preselected or predetermined antigen. The antigen binding site on a Fab fragment has a binding affinity or avidity similar to the antigen binding site on an immunoglobulin molecule.

In yet another embodiment, the present
15 transgenic plant contains a multimeric protein that is a F_v fragment comprised of at least a portion of an immunoglobulin heavy chain variable region and at least a portion of an immunoglobulin light chain variable region. The immunoglobulin heavy and light
20 chain variable regions autogenously associate with each other within the plant cell to assume a biologically active conformation having a binding site specific for a preselected or predetermined antigen. The antigen binding site on the F_v fragment has an
25 affinity or avidity for its antigen similar to the affinity displayed by the antigen binding site present on an immunoglobulin molecule.

In still another embodiment, the multimeric protein is an enzyme that binds a substrate and
30 catalyzes the formation of a product from the substrate. While the topology of the substrate binding site (ligand binding site) of the catalytic multimeric protein is probably more important for its activity than affinity (association constant or pK_a)
35 for the substrate, the subject multimeric protein has

an association constant for its preselected substrate greater than 10^3 M^{-1} , more usually greater than 10^5 M^{-1} or 10^6 M^{-1} and preferably greater than 10^7 M^{-1} .

When the multimeric protein produced in accordance with the present invention is an abzyme comprised of at least a portion of the immunoglobulin heavy chain variable region in association with another polypeptide chain, this other polypeptide chain includes at least the biologically active portion of an immunoglobulin light chain variable region. Together, these two polypeptides assume a conformation having a binding affinity or association constant for a preselected ligand that is different, preferably higher, than the affinity or association constant of either of the polypeptides alone, i.e., as monomers. Useful multimeric proteins contain one or both polypeptide chains derived from the variable region of the light and heavy chains of an immunoglobulin. Typically, polypeptides comprising the light (V_L) and heavy (V_H) variable regions are employed together for binding the preselected antigen.

1. Inserting Genes Coding For A First Polypeptide Into A First Member Of A Plant Species

Methods for isolating a gene coding for a desired first polypeptide are well known in the art. See, for example, Guide To Molecular Cloning Techniques in Methods In Enzymology, Volume 152, Berger and Kimmel, eds. (1987); and Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley and Sons, NY (1987) whose disclosures are herein incorporated by reference.

Genes useful in practicing this invention include genes coding for a polypeptide contained in

immunoglobulin products, immunoglobulin molecules, Fab fragments, F_v fragments, enzymes, receptors and abzymes. Particularly preferred are genes coding for immunoglobulin heavy and light chain variable regions.

5 Typically, the genes coding for the immunoglobulin heavy chain variable region and immunoglobulin light chain variable region of an immunoglobulin capable of binding a preselected antigen are used. These genes are isolated from cells obtained from a vertebrate,

10 preferably a mammal, which has been immunized with an antigenic ligand (antigen) against which activity is sought, i.e., a preselected antigen. The immunization can be carried out conventionally and antibody titer in the animal can be monitored to determine the stage

15 of immunization desired, which corresponds to the affinity or avidity desired. Partially immunized animals typically receive only one immunization and cells are collected therefrom shortly after a response is detected. Fully immunized animals display a peak

20 titer which is achieved with one or more repeated injections of the antigen into the host mammal, normally at two to three week intervals.

Usually three to five days after the last challenge, the spleen is removed and the genes coding

25 for immunoglobulin heavy and immunoglobulin light chain are isolated from the rearranged B cells present in the spleen using standard procedures. See Current Protocols in Molecular Biology, Ausubel et al., eds., John Wiley and Sons, NY (1987) and Antibodies: A

30 Laboratory Manual, Harlowe and Lane, eds., Cold Spring Harbor, NY (1988).

Genes coding for V_H and V_L polypeptides can be derived from cells producing IgA, IgD, IgE, IgG or IgM, most preferably from IgM and IgG, producing

35 cells. Methods for preparing fragments of genomic DNA

from which immunoglobulin variable region genes can be cloned are well known in the art. See for example, Herrmann et al., Methods in Enzymol., 152:180-183 (1987); Frischauf, Methods in Enzymol., 152:183-190 (1987); Frischauf, Methods in Enzymol., 152:199-212 (1987). (The teachings of the references cited herein are hereby incorporated by reference).

Probes useful for isolating the genes coding for immunoglobulin products include the sequences coding for the constant portion of the V_H and V_L sequences coding for the framework regions of V_H and V_L and probes for the constant region of the entire rearranged immunoglobulin gene, these sequences being obtainable from available sources. See for example, Early and Hood, Genetic Engineering, Setlow and Hollaender eds., Vol. 3:157-188, Plenum Publishing Corporation, NY (1981); and Kabat et al., Sequences of Immunological Interests, National Institutes of Health, Bethesda, MD (1987).

Genes coding for a polypeptide subunit of a multimeric protein can be isolated from either the genomic DNA containing the gene expressing the polypeptide or the messenger RNA (mRNA) which codes for the polypeptide. The difficulty in using genomic DNA is in juxtaposing the sequences coding for the polypeptide where the sequences are separated by introns. The DNA fragment(s) containing the proper exons must be isolated, the introns excised, and the exons spliced together in the proper order and orientation. For the most part, this will be difficult so the alternative technique employing mRNA will be the method of choice because the sequence is contiguous (free of introns) for the entire polypeptide. Methods for isolating mRNA coding for peptides or proteins are well known in the art. See,

for example, Current Protocols in Molecular Biology, Ausubel et al., John Wiley and Sons, NY (1987), Guide to Molecular Cloning Techniques, in Methods In Enzymology, Volume 152, Berger and Kimmel, eds. (1987), and Molecular Cloning: A Laboratory Manual, Maniatis et al., eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1982).

5 The polypeptide coding genes isolated above are typically operatively linked to an expression
10 vector. Expression vectors compatible with the host cells, preferably those compatible with plant cells are used to express the genes of the present invention. Typical expression vectors useful for
15 expression of genes in plants are well known in the art and include vectors derived from the tumor-inducing (Ti) plasmid of Agrobacterium tumefaciens described by Rogers et al., Meth. in Enzymol., 153:253-277 (1987). However, several other expression
20 vector systems are known to function in plants. See for example, Verma et al., PCT Publication No. WO87/00551; and Cocking and Davey, Science, 236:1259-1262 (1987).

The expression vectors described above contain expression control elements including the promoter.
25 The polypeptide coding genes are operatively linked to the expression vector to allow the promoter sequence to direct RNA polymerase binding and synthesis of the desired polypeptide coding gene. Useful in expressing
30 the polypeptide coding gene are promoters which are inducible, viral, synthetic, constitutive, temporally regulated, spatially regulated, and spatiotemporally regulated. The choice of which expression vector and ultimately to which promoter a polypeptide coding gene
35 is operatively linked depends directly, as is well known in the art, on the functional properties

segments by incubating the blunt-ended DNA segments with a large excess of synthetic linker molecules in the presence of an enzyme that is able to catalyze the ligation of blunt-ended DNA molecules, such as
5 bacteria phage T4 DNA ligase. Thus, the products of the reaction are DNA segments carrying synthetic linker sequences at their ends. These DNA segments are then cleaved with the appropriate restriction endonuclease and ligated into an expression vector
10 that has been cleaved with an enzyme that produces termini compatible with those of the synthetic linker. Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including New England BioLabs,
15 Beverly, MA.

Methods for introducing polypeptide coding genes into plants include Agrobacterium-mediated plant transformation, protoplast transformation, gene transfer into pollen, injection into reproductive
20 organs and injection into immature embryos. Each of these methods has distinct advantages and disadvantages. Thus, one particular method of introducing genes into a particular plant species may not necessarily be the most effective for another
25 plant species.

Agrobacterium tumefaciens-mediated transfer is a widely applicable system for introducing genes into plant cells because the DNA can be introduced into whole plant tissues, bypassing the need for
30 regeneration of an intact plant from a protoplast. The use of Agrobacterium-mediated expression vectors to introduce DNA into plant cells is well known in the art. See, for example, the methods described by Fraley et al., Biotechnology, 3:629 (1985) and Rogers
35 et al., Methods in Enzymology, 153:253-277 (1987).

Further, the integration of the Ti-DNA is a relatively precise process resulting in few rearrangements. The region of DNA to be transferred is defined by the border sequences and intervening DNA is usually inserted into the plant genome as described by Spielmann et al., Mol. Gen. Genet., 205:34 (1986) and Jorgensen et al., Mol. Gen. Genet., 207:471 (1987). Modern Agrobacterium transformation vectors are capable of replication in Escherichia coli as well as Agrobacterium, allowing for convenient manipulations as described by Klee et al., in Plant DNA Infectious Agents, T. Hohn and J. Schell, eds., Springer-Verlag, NY (1985) pp. 179-203. Further recent technological advances in vectors for Agrobacterium-mediated gene transfer have improved the arrangement of genes and restriction sites in the vectors to facilitate construction of vectors capable of expressing various polypeptide coding genes. The vectors described by Rogers et al., Methods in Enzymology, 153:253 (1987), have convenient multi-linker regions flanked by a promoter and a polyadenylation site for direct expression of inserted polypeptide coding genes and are suitable for present purposes.

In those plant species where Agrobacterium-mediated transformation is efficient, it is the method of choice because of the facile and defined nature of the gene transfer. However, few monocots appear to be natural hosts for Agrobacterium, although transgenic plants have been produced in asparagus using Agrobacterium vectors as described by Bytebier et al., Proc. Natl. Acad. Sci. U.S.A., 84:5345 (1987). Therefore, commercially important cereal grains such as rice, corn, and wheat must be transformed using alternative methods. Transformation of plant protoplasts can be achieved using methods based on

calcium phosphate precipitation, poly thylen glycol treatment, electroporation, and combinations of these treatments. See, for example, Potrykus et al., Mol. Gen. Genet., 199:183 (1985); Lorz et al., Mol. Gen. Genet., 199:178 (1985); Fromm et al., Nature, 319:791 (1986); Tchimiya et al., Mol. Gen. Genet., 204:204 (1986); Callis et al., Genes and Development, 1:1183 (1987); and Marcotte et al., Nature, 335:454 (1988).

Application of these systems to different plant species depends upon the ability to regenerate that particular plant species from protoplasts. Illustrative methods for the regeneration of cereals from protoplasts are described in Fujimura et al., Plant Tissue Culture Letters, 2:74 (1985); Toriyama et al., Theor Appl. Genet., 73:16 (1986); Yamada et al., Plant Cell Rep., 4:85 (1986); Abdullah et al., Biotechnology, 4:1087 (1986).

Agrobacterium-mediated transformation of leaf disks and other tissues appears to be limited to plant species that Agrobacterium tumefaciens naturally infects. Thus, Agrobacterium-mediated transformation is most efficient in dicotyledonous plants. However, the transformation of Asparagus using Agrobacterium can also be achieved. See, for example, Bytebier, et al., Proc. Natl. Acad. Sci., 84:5345 (1987).

To transform plant species that cannot be successfully regenerated from protoplast, other ways to introduce DNA into intact cells or tissues can be utilized. For example, regeneration of cereals from immature embryos or explants can be effected as described by Dasil, Biotechnology, 6:397 (1988). In addition, "particle gun" or high-velocity microprojectile technology can be utilized as well. Using such technology, DNA is carried through the cell wall and into the cytoplasm on the surface of small

(0.525 um) metal particles that have been accelerated to speeds of one to several hundred meters per second as described in Klein et al., Nature, 327:70 (1987); Klein et al., Proc. Natl. Acad. Sci. U.S.A., 85:8502 (1988); and McCabe et al., Biotechnology, 6:923 (1988). The metal particles penetrate through several layers of cells and thus allow the transformation of cells within tissue explants. Metal particles have been used to successfully transform corn cells and to produce fertile, stably transformed tobacco and soybean plants. Transformation of tissue explants eliminates the need for passage through a protoplast stage and thus speeds the production of transgenic plants.

DNA can be introduced into plants also by direct DNA transfer into pollen as described by Zhou et al., Methods in Enzymology, 101:433 (1983); D. Hess, Intern Rev. Cytol., 107:367 (1987); Luo et al., Plant Mol. Biol. Reporter, 6:165 (1988). Expression of polypeptide coding genes can be obtained by injection of the DNA into reproductive organs of a plant as described by Pena et al., Nature, 325:274 (1987). DNA can also be injected directly into the cells of immature embryos and the rehydration of desiccated embryos as described by Neuhaus et al., Theor. Appl. Genet., 75:30 (1987); and Benbrook et al., in Proceedings Bio Expo 1986, Butterworth, Stoneham, MA, pp. 27-54 (1986).

The regeneration of plants from either single plant protoplasts or various explants is well known in the art. See, for example, Methods for Plant Molecular Biology, A. Weissbach and H. Weissbach, eds., Academic Press, Inc., San Diego, CA (1988). This regeneration and growth process includes the steps of selection of transformant cells and shoots,

rooting the transformant shoots and growth of the plantlets in soil.

The regeneration of plants containing the foreign gene introduced by Agrobacterium tumefaciens from leaf explants can be achieved as described by Horsch et al., Science, 227:1229-1231 (1985). In this procedure, transformants are grown in the presence of a selection agent and in a medium that induces the regeneration of shoots in the plant species being transformed as described by Fraley et al., Proc. Natl. Acad. Sci. U.S.A., 80:4803 (1983). This procedure typically produces shoots within two to four weeks and these transformant shoots are then transferred to an appropriate root-inducing medium containing the selective agent and an antibiotic to prevent bacterial growth. Transformant shoots that rooted in the presence of the selective agent to form plantlets are then transplanted to soil to allow the production of roots. These procedures will vary depending upon the particular plant species employed, such variations being well known in the art.

2. Inserting A Gene Coding For A Second Polypeptide Into A Second Member Of A Plant Species

Useful genes include those genes coding for a second polypeptide that can autogenously associate with the first polypeptide in such a way as to form a biologically functional multimeric protein. The methods used to introduce a gene coding for this second polypeptide into a second member of a plant species are the same as the methods used to introduce a gene into the first member of the same plant species and have been described above.

3. Producing A Population of Progeny
From The First And Second
Transformants

5 A population of progeny can be produced
from the first and second transformants of a plant
species by methods well known in the art including
those methods known as cross fertilization described
by Mendel in 1865 (an English translation of Mendel's
original paper together with comments and a
10 bibliography of Mendel by others can be found in
Experiments In Plant Hybridization, Edinburgh,
Scotland, Oliver Boyd, eds., 1965).

15 4. Isolating Progeny Containing The
Multimeric Protein

Progeny containing the desired multimeric
protein can be identified by assaying for the presence
of the biologically multimeric protein using assay
methods well known in the art. Such methods include
20 Western blotting, immunoassays, binding assays, and
any assay designed to detect a biologically functional
multimeric protein. See, for example, the assays
described in Immunology: The Science of Self-Nonself
Discrimination, Klein, John Wiley and Sons, NY, NY
25 (1982).

Preferred screening assays are those where the
biologically active site on the multimeric protein is
detected in such a way as to produce a detectible
signal. This signal may be produced directly or
30 indirectly and such signals include, for example, the
production of a complex, formation of a catalytic
reaction product, the release or uptake of energy, and
the like. For example, a progeny containing an
antibody molecule produced by this method may be
35 processed in such a way to allow that antibody to bind

its antigen in a standard immunoassay such as an ELISA or a radio-immunoassay similar to the immunoassays described in Antibodies: A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988).

A further aspect of the present invention is a method of producing a multimeric protein comprised of a first and a second polypeptide. Generally, the method combines the elements of cultivating a plant of the present invention, and harvesting the plant that was cultivated to produce the desired multimeric protein.

A plant of the present invention containing the desired multimeric protein comprised of a first polypeptide and a second polypeptide is cultivated using methods well known to one skilled in the art. Any of the transgenic plants of the present invention may be cultivated to isolate the desired multimeric protein they contain.

After cultivation, the transgenic plant is harvested to recover the produced multimeric protein. This harvesting step may consist of harvesting the entire plant, or only the leaves, or roots of the plant. This step may either kill the plant or if only the portion of the transgenic plant is harvested may allow the remainder of the plant to continue to grow.

In preferred embodiments this harvesting step further comprises the steps of:

- (i) homogenizing at least a portion of said transgenic plant to produce a plant pulp;
- (ii) extracting said multimeric protein from said plant pulp to produce a multimeric protein containing solution; and
- (iii) isolating said multimeric protein from said solution.

At least a portion of the transgenic plant is homogenized to produce a plant pulp using methods well known to one skilled in the art. This homogenization may be done manually, by a machine, or by a chemical means as long as the transgenic plant portions are broken up into small pieces to produce a plant pulp. This plant pulp consists of a mixture of varying sizes of transgenic plant particles. The size of the plant particles and the amount of variation in size that can be tolerated will depend on the exact method used to extract the multimeric protein from the plant pulp and these parameters are well known to one skilled in the art.

The multimeric protein is extracted from the plant pulp produced above to form a multimeric protein containing solution. Such extraction processes are common and well known to one skilled in this art. For example, the extracting step may consist of soaking or immersing the plant pulp in a suitable solvent. This suitable solvent is capable of dissolving the multimeric protein present in the plant pulp to produce a multimeric protein containing solution. Solvents useful for such an extraction process are well known to those skilled in the art and include aqueous solvents, organic solvents and combinations of both.

The multimeric protein is isolated from the solution produced above using methods that are well known to those skilled in the art of protein isolation. These methods include, but are not limited to, immuno-affinity purification and purification procedures based on the specific size, electrophoretic mobility, biological activity, and/or net charge of the multimeric protein to be isolated.

C. Utilization of the Transgenic Plant

The present invention also provides a novel method for separating a preselected ligand from a fluid sample. The method combines the following elements:

1. Commingling the fluid sample with plant cells from a transgenic plant from the present invention to form an admixture.

2. Maintaining this admixture for a time period sufficient for the ligand to enter the plant cells and bind the multimeric protein to form a complex within the plant cells.

3. Removing the complex-containing plant cells from the admixture and thereby separating the ligand from the fluid sample.

The fluid sample is commingled with the plant cells from a transgenic plant of the present invention that contain a multimeric protein. This multimeric protein can be a receptor, an enzyme, an immunoglobulin product, an immunoglobulin molecule or fragment thereof, or an abzyme. One skilled in the art will understand that this multimeric protein must be capable of binding the preselected ligand. The fluid sample can be a liquid or a gas. In either case the commingling may consist of placing the plant cells in either the liquid or the gas. Alternatively, the plant cells may be thoroughly mixed with the fluid sample. This commingling must bring the fluid sample in intimate contact with the plant cells to form an admixture.

This admixture is maintained for a time period sufficient to allow the ligand present in the fluid sample to enter the cells. This process may be a passive process as in diffusion or may occur through the application of energy to the system, such as

applying high pressure to the fluid sample to force it into the plant cells. The amount of time required for the ligand to enter the plant cells is known to one skilled in the art and can be predetermined to optimize such time period. After entering the plant cells the ligand binds the multimeric protein to form a complex. When the multimeric protein is a receptor, the complex formed is a receptor-ligand complex. When the multimeric protein is an immunoglobulin, immunoglobulin molecule, a portion of an immunoglobulin molecule, a Fab fragment, or a Fv fragment the complex formed is an immuno-reaction complex. When the multimeric protein is an enzyme and the ligand is a substrate the complex formed is an enzyme-substrate complex. When the multimeric protein is an abzyme the complex formed is an immuno-reaction complex.

After the complex is formed in the plant cells, the complex-containing plant cells are removed from the admixture thereby separating the ligand from the fluid sample. Methods for removing the plant cells from the admixtures are well known to those skilled in the art and include mechanical removal, filtration, sedimentation and other separation means.

When the plant cells utilized for this method constitute a viable plant, this expedient concentrates the ligand within the plant. When the ligand is an important nutrient, this results in that plant concentrating that particular nutrient within its cells, thereby enhancing the nutritional value of the plant. When the ligand is an environmental pollutant, this pollutant is concentrated within the plant cells and thus is removed from the environment. Of course, for this method to be applicable, the ligand must be able to enter the plant cells. The ligands that can

enter the plant cells are well known to those skilled in the art.

The present invention also contemplates a method of separating a metal ion from a fluid sample containing the metal ion. This particular method includes the following steps:

1. Admixing to the fluid sample a chelating agent to form a chelating admixture.

2. Maintaining the chelating admixture for a time period sufficient for the metal ion to bind the chelating agent and form a metal ion chelation complex.

3. Commingling the metal ion chelation complex with plant cells of the present invention to form a binding admixture.

4. Maintaining the binding admixture for a time period sufficient for the metal ion chelation complex to enter the plant cells and bind the multimeric protein to form a reaction complex.

5. Removing the reaction complex-containing plant cells from the binding admixture and thereby separating the metal ion from the fluid sample.

Chelating agents useful in practicing this method include ethylene diamine tetra acetic acid (EDTA) and Bis(bis-carboxy methyl amino propyl) phenyl isothiocyanate (CITC). See for example, Meares, et al., Analytical Biochemistry, 142:68-78 (1984). The fluid sample may be either a gas or liquid sample and, when admixed with a chelating agent, forms a chelating admixture.

The chelating admixture is maintained for a time period sufficient for the metal to bind the chelating agent and form a metal ion chelation complex. The amount of time required for the metal

ion to bind the chelating agent will depend upon at least the type of chelating agent employed and the concentration of the metal. The metal ion chelation complex is formed when at least one metal ion
5 associates with its chelating agent and becomes bound to that chelating agent to form a complex.

This metal ion chelation complex is commingled with plant cells of the present invention. These plant cells contain a multimeric protein capable of
10 specifically binding the metal ion chelation complex. For example, the plant cells may contain an immunoglobulin that is immunospecific for a metal chelation complex similar to those immunoglobulin molecules described by Reardon, et al., Nature,
15 316:265-268 (1985) and Meares, et al., Analytical Biochemistry, 142:68-78 (1984).

The binding admixture is maintained for a time period sufficient for the metal ion chelation complex to enter the plant cells and bind the multimeric
20 protein to form a reaction complex with the plant cells. The binding admixture must be maintained under conditions allow the metal ion chelation complex to bind the multimeric protein. Such conditions are well known to those skilled in the art. The amount of time
25 required for the metal ion chelation complex to enter the plant cell will vary and will depend at least upon the concentration and size of the metal chelation complex. The metal ion chelation complex may enter the plant cells passively, for example by diffusion,
30 or may be forced under pressure into the plant cells. The reaction complex formed when the metal ion chelation complex binds to the multimeric protein present in the plant cells consists of the metal ion bound to the chelating agent, the chelating agent and
35 th multimeric protein. The reaction complex-

containing plant cells are then removed from the binding admixture thereby separating the metal ion from the fluid sample. The plant cells may be removed using the methods well known to those skilled in the art and include mechanically removing, filtration, sedimentation and other separation means. When the plant cells utilized for this method constitute a viable plant, this method concentrates the metal within the plant.

Transgenic plants of the present invention can be produced from any sexually crossable plant species that can be transformed using any method known to those skilled in the art. Useful plant species are dicotyledons including tobacco, tomato, the legumes, alfalfa, oaks, and maples;; monocotyledons including grasses, corn, grains, oats, wheat, and barley; and lower plants including gymnosperms, conifers, horsetails, club mosses, liver warts, horn warts, mosses, algae, gametophytes, sporophytes of pteridophytes.

The transgenic plants of the present invention contain polypeptide coding genes operatively linked to a promoter. Useful promoters are known to those skilled in the art and include inducible promoters, viral promoters, synthetic promoters, constitutive promoters, temporally regulated promoters, spatially regulated promoters, and spatiotemporally regulated promoters.

In preferred embodiments, the transgenic plants of the present invention contain an immunoglobulin product. Useful immunoglobulin products are well known to one skilled in the immunoglobulin art and include an immunoglobulin heavy chain, an immunoglobulin molecule comprised of a heavy and a light chain. One half of an immunoglobulin

molecule, a Fab fragment, a Fv fragment, and proteins known as single chain antigen binding proteins. The structures of immunoglobulin products are well known to those skilled in the art and described in Basic and Clinical Immunology, by Stites, et al., 4th ed., Lange Medical Publications, Los Altos, CA. The structure of single chain antigen binding proteins has been described by Bird et al., Science, 242:423-426 (1988) and U.S. Patent No. 4,704,692 by Ladner.

The immunoglobulins, or antibody molecules, are a large family of molecules that include several types of molecules, such as IgD, IgG, IgA, IgM and IgE. The antibody molecule is typically comprised of two heavy (H) and light (L) chains with both a variable (V) and constant (C) region present on each chain. Several different regions of an immunoglobulin contain conserved sequences useful for isolating the immunoglobulin genes using the polymerase chain reaction. Extensive amino acid and nucleic acid sequence data displaying exemplary conserved sequences is compiled for immunoglobulin molecules by Kabat et al., in Sequences of Proteins of Immunological Interest, National Institute of Health, Bethesda, MD (1987).

The V region of the H or L chain typically comprises four framework (FR) regions (Figure 1) each containing relatively lower degrees of variability that includes lengths of conserved sequences. The use of conserved sequences from the FR1 and FR4 (J region) framework regions of the V_H is a preferred exemplary embodiment and is described herein in the Examples. Framework regions are typically conserved across several or all immunoglobulin types and thus conserved sequences contained therein are particularly suited for isolating the variabl types.

One particularly useful immunoglobulin product is an immunoglobulin heavy chain. An immunoglobulin heavy chain consists of an immunoglobulin heavy chain variable region and an immunoglobulin constant region.

5 The immunoglobulin heavy chain variable region is a polypeptide containing an antigen binding site (and antibody combining site). Therefore, the immunoglobulin heavy chain variable region is capable of specifically binding a particular epitope.

10 Preferably, the V_H will be from about 110 to about 125 amino acid residues in length. The amino acid residue sequence will vary widely, depending the particular antigen the V_H is capable of binding. Usually, there will be at least two cysteines separated by about 60-

15 75 amino acid residues that are joined to one another by a disulfide bond.

The immunoglobulin constant region (C_H) can be of the alpha, gamma 1, gamma 2, gamma 3, delta, mu, or epsilon human isotypes. If the immunoglobulin heavy

20 chain is derived from a mouse the C_H may be of the alpha, gamma 1, gamma 2a, gamma 2b, gamma 3, delta, mu, or epsilon isotypes. The C_H will be of an isotype that is normally present in the animal species that it was isolated from. The C_H may also consist of domains

25 derived from different isotypes to enhance or confer a given biological function. Genes containing the DNA sequence from several different constant region isotypes may be combined to produce a chimeric gene that encodes a chimeric C_H polypeptide. The DNA and

30 protein sequences are easily obtained from available sources. See for example, Early Hood, Genetic Engineering, Setlow and Hollaender, eds., Vol. 3, Plenum Publishing Corporation, (1981), pages 157-188; and Kabaty et al., Sequences of Immunological

35 Interest, National Institutes Of Health, Bethesda, MD

(1987). These two sources also contain a number of sequences for V_H , V_L and C_L genes and proteins.

Preferred immunoglobulin products are those that contain an immunoglobulin heavy chain described above and an immunoglobulin light chain. Immunoglobulin light chains consist of an immunoglobulin light chain variable region (V_L) and an immunoglobulin light chain constant region. The V_L will be from about 95 to about 115 amino acid residues in length. One skilled in the art will understand that there are two isotypes of C_L that are present in both human and mouse, the lambda isotype and the kappa isotype.

In other preferred embodiments the immunoglobulins product consists of V_H alone, or of a V_H associated with a V_L to form a Fv fragment.

The contemplated transgenic plants contain a multimeric protein. This multimeric protein may be an immunoglobulin product described above, an enzyme, a receptor capable of binding a specific ligand, or an abzyme.

An enzyme of the present invention is a multimeric protein wherein at least two polypeptide chains are present. These two polypeptide chains are encoded by genes introduced into the transgenic plant by the method of the present invention. Useful enzymes include aspartate transcarbamylase and the like.

In another preferred embodiment is a receptor capable of binding a specific ligand. Typically this receptor is made up of at least two polypeptide chains encoded by genes introduced into the transgenic plant by a method of the present invention. Examples of such receptors and their respective ligands include h moglobin, O_2 ; protein kinases, cAMP; and th like.

In another preferred embodiment of the present invention the immunoglobulin product present is an abzyme constituted by either an immunoglobulin heavy chain and its associated variable region, or by an immunoglobulin heavy chain and an immunoglobulin light chain associated together to form an immunoglobulin molecule, a Fab, Fv or a substantial portion of an immunoglobulin molecule. Illustrative abzymes include those described by Tramontano et al., Science, 234: 1566-1570 (1986); Pollack et al., Science, 234: 1570-1573 (1986); Janda et al., Science, 241: 1188-1191 (1988); and Janda et al., Science, 244: 437-440 (1989).

Typically a multimeric protein of the present invention contains at least two polypeptides; however, more than two peptides can also be present. Each of these polypeptides is encoded by a separate polypeptide coding gene. The polypeptides are associated with one another to form a multimeric protein by disulfide bridges, by hydrogen bonding, or like mechanisms.

Included as part of the present invention are transgenic plants that are produced from or are the progeny of a transgenic plant of the present invention. These transgenic plants contain the same multimeric protein as that contained in the parental transgenic plant. Such plants may be generated either by asexually propagating the parental plant or by self-pollination. The process of asexually propagating and self-pollinating a plant are well known.

In a further aspect, the present invention contemplates a transgenic plant that contains a complex. Generally, such a complex-containing transgenic plant is obtained by adding a chelating

agent to a fluid sample to form a chelating admixture, maintaining the admixture for a time period sufficient for any metal present in the fluid sample to bind the chelating agent and form a metal chelation complex, commingling the metal chelation complex with transgenic plant cells of the present invention to form a binding admixture, and maintaining the binding admixture for a time period sufficient for the metal chelation complex to enter the plant cells and bind the multimeric protein present in the plant cells to form a complex within the plant cells.

Also contemplated by the present invention are transgenic plants containing a reaction complex consisting of a metal chelation complex and an immunoglobulin product. Typically, this transgenic plant will be produced by a method of the present invention.

D. Biologically Active Glycopolyptide Multimers

The present invention contemplates a biologically active glycopolyptide multimer comprising at least two polypeptides, one of the polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a core portion and N-acetylglucosamine-containing outer branches, such that the multimer is free from sialic acid residues.

In preferred embodiments, the biologically active glycopolyptide multimer includes an amino acid residue sequence of an immunoglobulin superfamily molecule, such as an amino acid residue sequence of an immunoglobulin, a molecule of the T cell receptor complex, a major histocompatibility complex antigen and the like. Particularly preferred are biologically

active glycopolypeptide multimers that contain an amino acid residue sequence of an immunoglobulin heavy chain, an immunoglobulin heavy chain variable region or a portion of an immunoglobulin heavy chain variable region. Glycopolypeptide multimers having an amino acid residue sequence of an immunoglobulin light chain, and immunoglobulin light chain variable region and portions of an immunoglobulin light chain variable region are also preferred.

10 In a preferred embodiment, the biologically active glycopolypeptide multimer comprises a polypeptide having a glycosylated core portion as well as N-acetylglucosamine containing outer branches and an amino acid residue sequence of an immunoglobulin molecule that is bonded to at least one other polypeptide including another amino acid residue sequence. In preferred embodiments, the other polypeptide may include an amino acid residue sequence of an immunoglobulin superfamily molecule, an immunoglobulin molecule, an immunoglobulin heavy chain, an immunoglobulin heavy chain variable region, a portion of an immunoglobulin heavy chain variable region, an immunoglobulin light chain, an immunoglobulin light chain variable region, or a portion of an immunoglobulin light chain region.

25 In other preferred embodiments, the glycopolypeptide multimer further comprises immunoglobulin J chain bonded to the immunoglobulin molecule or a portion of the immunoglobulin molecule present in the glycopolypeptide multimer. J chain is a polypeptide that is associated with polymeric IgA and IgM and other immunoglobulins such as IgG, IgD, IgE, and the other various subclasses of these immunoglobulin isotypes.

The amino acid composition of both human and mouse J chain has been described by Mole et al., Biochemistry, 16:3507 (1977), Max and Korsm y r, J. Exp. Med., 161:832 (1985), Cann et al., Proc. Natl. Acad. Sci., USA, 79:6656 (1982), and Koshland, Annu. Rev. Immunol., 3:425 (1985). J chain has 137 amino acid residues with a high proportion of acidic amino acids, low numbers of glycine, threonine, cysteine, and only one methionine. The J chain contains 8 cysteine residues, 6 of which are involved in the formation of intrachain disulfide bonds and 2 are connected to the penultimate cysteine residues of the immunoglobulin heavy chain such as the alpha or mu heavy chain as described by Mendez et al., Biochem. Biophys. Res. Commun., 55:1291 (1973), Mesteckey et al., Proc. Natl. Acad. Sci., USA, 71:544 (1974), Mesteckey and Schrohenloher, Nature, 249:650 (1974).

In preferred embodiments, the glycopolypeptide multimer also comprises a secretory component bonded to the Fc region of the immunoglobulin heavy chain amino acid residue sequence present in the glycopolypeptide multimer. Secretory component is comprised of a single polypeptide chain with 549 to 558 amino acid residues and large amounts of carbohydrates attached by N-glycosidic bonds to asparagine residues as 5-7 oligosaccharide side chains. See, Mostov et al., Nature, 308:37 (1984); Eiffert et al., Hoppe Seyler's C. Physiol. Chem., 365:1489 (1984); Heremans, N The Antigens, M. Sela ed., 2:365, Academic Press New York (1974); Tomana et al., Ana. Biochem., 89:110 (1978); Purkayasthaa et al., J. Biol. Chem., 254:6583 (1979); and Mizoguchi et al., J. Biol. Chem., 257:9612 (1982). Secretory component contains 20 cysteine residues that are involved in intrachain disulfide bonding. In

preferred embodiments, secretory component is disulfide bonded to a cysteine residue present in the Fc region of the immunoglobulin heavy chain present in the glycopolyptide multimer.

5 The present invention contemplates a glycopolyptide multimer comprises a polypeptide having a glycosylated core portion as well as a N-acetylglucosamine containing outer branches and the multimer is free from detectable sialic acid residues.

10 The polypeptide has a glycosylated core portion including an N-acetylglucosamine oligosaccharide bonded via its C(1) carbon directly to the amide group of an asparagine amino acid residue present in the polypeptide. The glycosylated core portion has the

15 structure $\text{Man}\alpha 1-3(\text{Man}\alpha 1-6) \text{Man}\beta 11-4\text{GlcNAc}\beta 1-4 \text{GlcNAc}-$ Asn contained within the boxed area in Figure 6. The polypeptide also has outer oligosaccharide branches (outer branches) that contain N-acetylglucosamine. Both complex and hybrid asparagine-linked

20 oligosaccharides contain N-acetylglucosamine containing outer branches, while high mannose oligosaccharides do not. Bacterial cells do not include glycosylated core portions attached to asparagine amino acids. Yeast cells do not have

25 asparagine-linked oligosaccharides of either the complex or hybrid type and therefore yeast do not have N-acetylglucosamine containing outer branches. Plant cells are capable of producing a polypeptide having a glycosylated core portion linked to an asparagine

30 amino acid as well as N-acetylglucosamine containing outer branches.

 The glycopolyptide multimer comprises a polypeptide that has a glycosylated core portion as well N-acetylglucosamine containing outer branches and

35 in detectable sialic acid residues and the entire the

multimer is free from detectable sialic acid residues. Sialic acid, the predominant terminal carbohydrate of mammalian glycoproteins, has not been identified as a carbohydrate residue of plant proteins. The terminal
5 carbohydrate residues found in plants include xylose, fucose, N-acetylglucosamine, mannose or galactose as has been described by Sturm et al., J. Biol. Chem., 262:13392 (1987). In other respects, plant glycoproteins and carbohydrates attached to those
10 proteins are very similar to mammalian glycoproteins. A glycopolypeptide multimer produced in a plant comprises a polypeptide having a glycosylated core portion as well as N-acetylglucosamine containing outer branches but is free from detectable sialic acid
15 residues.

A gene coding for a polypeptide having within its amino acid residue sequence, the N-linked glycosylation signal, asparagine-X-serine/threonine, where X can be any amino acid residue except possibly
20 proline or aspartic acid, when introduced into a plant cell would be glycosylated via oligosaccharides linked to the asparagine residue of the sequence (N-linked). See, Marshall, Ann. Rev. Biochem., 41:673 (1972) and Marshall, Biochem. Soc. Symp., 40:17 (1974) for a
25 general review of the polypeptide sequences that function as glycosylation signals. These signals are recognized in both mammalian and in plant cells. However in plant cells these signals do not result in asparagine-linked oligosaccharides that contain
30 terminal sialic acid residues as are found in mammalian cells when expressed in a plant cell, a polypeptide containing the N-linked glycosylation signal sequence would be glycosylated to contain a glycosylated core portion as well as N-
35 ac tyglucosamine containing outer branches and would

be free from detectable sialic acid residues.

A glycop lyopeptide multimer, a protein, or a polypeptide of the present invention is fr from detectable sialic acid residues as evidenced by its lack of specific binding to lectins specific for sialic acid such as wheat germ agglutinin or Ricinus communis, agglutinin. Methods for determining the binding of a glycosylated polypeptide chain to a particular lectin are well known in the art. See, e.g., Faye et al., Ana. Biochem., 149:218 (1985) and Goldstein et al., Adv. Carbohydr. Chem. Biochem., 35:127 (1978). Typical methods for determining whether a glycosylated polypeptide chain binds to a particular lectin include methods using lectin columns, and methods where the glycosylated polypeptide is bound to nitrocellulose and probed with a biotinylated lectin. The exact specificity of the lectin may be determined by competing the lectin binding with a particular oligosaccharide such as a sialic acid residue. The common sialic acid residues are shown in Figure 7.

Immunoglobulin superfamily molecules, and immunoglobulins may have various carbohydrate groups attached to them. Typically the carbohydrate is found on the immunoglobulin heavy chain constant region except for a few instances when the tripeptide acceptor sequence asparagine-X-serine/threonine (N-linked signal), is found within the heavy chain variable region. Other immunoglobulin superfamily molecules containing the tripeptide acceptor sequence (N-linked glycosylation sequence) within its amino acid residue sequence would also contain carbohydrate groups attached to the asparagine of that tripeptide acceptor sequence. Figure 8 shows the typical carbohydrate groups attached to 7 human heavy chains

as described by Jeske and Capra, in Fundamental Immunology, W.E. Paul, ed., Raven Press, New York, NY (1984). The carbohydrate attachment sites are highly conserved between various species and the comparable classes of immunoglobulin heavy chains. Table B shows the various oligosaccharides on each of the human immunoglobulin heavy chains.

Table B
Structural Characteristics of Human Immunoglobulin Heavy Chains

<u>Whole Chain</u>			<u>Constant Region</u>			<u>No. of residues (approximate)</u>	
<u>Chain</u>	<u>Domains</u>	<u>Interchain bridges</u>	<u>Position of H-L bridge</u>	<u>Oligosacchrides</u>			
				<u>GlcN</u>	<u>GalN</u>	<u>Hinge</u>	<u>C Region</u>
gamma 1	4	3	220	1	0	15	330
gamma 2	4	5	131	1	0	12	325
gamma 3	4	12	131	1	0	62	375
gamma 4	4	3	131	1	0	14	325
alpha 1	4	5	133	2	5	26	350
alpha 2 A2m(1)	4	4	missing	4	0	13	340
alpha 2 A2m(2)	4	5	133	5	0	13	340
mu	5	4	140	5	0	0	450
epsilon	5	3	127	6	0	0	420
delta	4	2	128	3	4 or 5	64	380

Preferably, the polypeptide present in the glycopolypeptide multimer includes the N-linked glycosylation signal within the immunoglobulin molecule amino acid residue sequence. In other preferred embodiments, the N-linked glycosylation is present in the region of the polypeptide that is not an immunoglobulin residue sequence.

In preferred embodiments, the biologically active glycopolypeptide multimer comprises secretory IgA. Secretory IgA is made up of four immunoglobulin alpha heavy chains, four immunoglobulin light chains, J chain and secretory component all bonded together to form a secretory IgA molecule containing an IgA dimer. The secretory IgA molecule contains heavy and light chain variable regions that bind specifically to an antigen. The secretory IgA molecule may contain either IgA₁ or IgA₂ molecules. For a general discussion of secretory IgA, see Mesteckey et al., Advances in Immunology, 40:153 (1987).

The final assembled secretory IgA of animals is the product of two distinct cell types: plasma cells that produce IgA with attached J chain and epithelial cells that produce secretory IgA. The transytosis and secretion of the complex is the result of the membrane only at the luminal surface of the cell. The interaction of the four components of the complex (alpha, gamma, J, SC) results in an immunoglobulin structure which is exceptionally resistant to the degradative environment associated with mucosal surfaces.

In other preferred embodiments the biologically active glycopolypeptide multimer is a secretory IgM molecule that contains five IgM molecules, three J chain molecules and secretory component all disulfide bonded together.

Both secretory immunoglobulins (IgM and IgA) are resistant to proteolysis and degradation and therefor are active when present on mucosal surfaces such as the lungs or the gastrointestinal tract. See, 5 Tomasi, N. Basic and Clinical Immunology, p. 198, Lange Medical Publications, Los Altos, CA (1982).

In preferred embodiments, a biologically active glycopolypeptide multimer has within it at least on catalytic site. This catalytic site may be 10 an enzymatic site that is formed by one or more polypeptides. The catalytic site present is typically defined by an amino acid residue sequence that is known to form a catalytic site alone or together with the amino acid residue sequences of other 15 polypeptides. This catalytic site may be the active site of an enzyme, or the binding site of an immunoglobulin. See, e.g., Tramontano et al., Science, 234:1566 (1986). The present invention also contemplates other enzymes containing a catalytic site 20 such as the enzymes described in Biochemistry Worth Publishers, Inc., NY (1975).

In other preferred embodiments, the present invention contemplates a biologically active glycopolypeptide multimer comprising a polypeptide 25 having a glycosylated core portion as well as N-acetylglucosamine containing outer branches and includes an immunoglobulin molecule amino acid residue sequence, bonded to another polypeptide including a different immunoglobulin molecule amino acid residue 30 sequence where the multimer is free from detectable sialic acid.

Catalytic glycopolypeptide multimers are contemplated wherein the catalytic site of the glycopolypeptide multimer is comprised of a first and 35 second portion. The first portion of the catalytic

5 sit is also defined by an immunoglobulin amino acid
residue sequence. The second portion of the catalytic
site is defined by a different immunoglobulin amino
acid residue sequence. The first and second portions
10 of the catalytic site are associated together to form
a greater portion of the catalytic site. In more
preferred embodiments, the first portion of the
catalytic site is defined by an immunoglobulin heavy
chain variable region amino acid residue sequence and
15 the second portion of the catalytic site is defined by
an immunoglobulin light chain variable region amino
acid residue sequence that is associated with the
heavy chain amino acid residue sequence to form a
larger portion at the catalytic site.

15 The present invention also contemplates a
biologically active glycopolypeptide multimer
comprising:

20 (i) A polypeptide having a glycosylated core
portion as well as a N-acetylglucosamine-containing
outer branches and an immunoglobulin molecule amino
acid residue sequence and the polypeptide does not
bind to a mouse immunoglobulin binding lectin; and

25 (ii) another polypeptide containing a
different immunoglobulin molecule amino acid residue
sequence, where this another polypeptide is bonded to
the polypeptide.

30 Mouse immunoglobulin binding lectins include
lectins that specifically bind terminal sialic acid
residues such as wheat germ agglutinin and Ricinus
communis agglutinin. A mouse immunoglobulin binding
lectin is specific for terminal sialic acid residues
and thus does not bind an immunoglobulin produced in a
plant cell because immunoglobulins produced in plants
do not contain terminal sialic acid residues. See,

Osawa et al., Ana. Rev. Biochem., 56:21-42 (1987) for a general discussion of lectin binding properties.

E. Passive Immunizations Using
Immunoglobulins Produced in Plants

5 Methods of passively immunizing an animal
against a preselected ligand by contacting a
composition comprising a biologically active
glycopolypeptide multimer of the present invention
10 that is capable of binding a preselected ligand with a
mucosal surface of an animal are contemplated by the
present invention.

Biologically active glycopolypeptide multimers
such as immunoglobulin molecules capable of binding a
15 preselected antigen can be efficiently and
economically produced in plant cells. These
immunoglobulin molecules do not contain sialic acid
yet do contain core glycosylated portions and N-
acetylglucosamine containing outer branches. In
20 preferred embodiments, the immunoglobulin molecule is
either IgA, IgM, secretory IgM or secretory IgA.

Secretory immunoglobulins, such as secretory
IgM and secretory IgA are resistant to proteolysis and
denaturation and therefore are desirable for use in
25 harsh environments. Contemplated harsh environments
include acidic environments, protease containing
environments, high temperature environments, and other
harsh environments. For example, the gastrointestinal
tract of an animal is a harsh environment where both
30 proteases and acid are present. See, Kobayishi et
al., Immunochemistry, 10:73 (1973). Passive
immunization of the animal is produced by contacting
the glycopolypeptide multimer with a mucosal surface
of the animal. Animals contain various mucosal
35 surfaces including the lungs, the digestive tract, the

nasopharyngeal cavity, the urogenital system, and the like. Typically, these mucosal surfaces contain cells that produce various secretions including saliva, lacrimal fluid, nasal fluid, tracheobronchial fluid, intestinal fluid, bile, cervical fluid, and the like.

In preferred embodiments the glycopolypeptide multimer, such as the immunoglobulin molecule is immunospecific for a preselected antigen. Typically, this antigen is present on a pathogen that causes a disease that is associated with the mucosal surface such as necrotizing enterocolitis, diarrheal disease, and cancer caused by carcinogen absorption in the intestine. See e.g., McNabb and Tomasi, Ann. Rev. Microbiol., 35:477 (1981) and Lawrence et al., Science, 243:1462 (1989). Typical pathogens that cause diseases associated with a mucosal surface include both bacterial and viral pathogens such as E. coli, S. typhimurium, V. cholera, and S. mutans. The glycopolypeptide multimer is capable of binding to these pathogens and preventing them from causing mucosal associated or mucosal penetrating diseases.

In preferred embodiments, the composition contacted with the animal mucosal surface comprises a plant material and a biologically active glycopolypeptide multimer that is capable of binding a preselected ligand. The plant material present may be plant cell walls, plant organelles, plant cytoplasm, intact plant cells containing the glycopolypeptide multimer, viable plants, and the like. This plant cell material is present in a ratio from about 10,000 grams of plant material to about 100 nanograms of glycopolypeptide multimer, to about 100 nanograms of plant material for each 10 grams of glycopolypeptide multimer present. In more preferred embodiments, the plant material is present in a ratio from about 10,000

grams of plant material for each 1 mg of glycopolypeptide multimer present, to about a ratio of 100 nanograms of plant material present for each gram of glycopolypeptide multimer present. In other preferred embodiments, the plant material is present in a ratio from about 10,000 grams of plant material for each milligram of glycopolypeptide multimer present to about 1 mg of plant material present for each 500 mg of glycopolypeptide multimer present.

In preferred embodiments, the composition comprising the biologically active glycopolypeptide multimer is a therapeutic composition. The preparation of therapeutic compositions which contain polypeptides or proteins as active ingredients is well understood in the art. Therapeutic compositions may be liquid solutions or suspensions, solid forms suitable for solution in, or suspension in a liquid prior to ingestion may also be prepared. The therapeutic may also be emulsified. The active therapeutic ingredient is typically mixed with inorganic and/or organic carriers which are pharmaceutically acceptable and compatible with the active ingredient. The carriers are typically physiologically acceptable excipients comprising more or less inert substances when added to the therapeutic composition to confer suitable consistencies and form to the composition. Suitable carriers are for example, water, saline, dextrose, glycerol, and the like and combinations thereof. In addition, if desired the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents and pH buffering agents which enhance the effectiveness of the active ingredient. Therapeutic compositions containing carriers that have nutritional value are also contemplated.

In preferred embodiments, a composition containing a biologically active glycopolypeptid multimer comprises an immunoglobulin molecule that is immunospecific for a pathogen antigen. Pathogens are any organism that causes a disease in another organism. Particularly preferred are immunoglobulins that are immunospecific for a mucosal pathogen antigen. A mucosal pathogen antigen is present on a pathogen that invades an organism through mucosal tissue or causes mucosal associated diseases. Mucosal pathogens include lung pathogens, nasal pathogens, intestinal pathogens, dental pathogens, and the like. For a general discussion of pathogens, including mucosal pathogens, see, Davis et al., Microbiology, 3rd ed., Harper and Row, Hagerstown, MD (1980).

Antibodies immunospecific for a pathogen may be produced using standard monoclonal antibody production techniques. See, Antibodies: A Laboratory Manual, Harlow et al., eds., Cold Spring Harbor, NY (1988). The genes coding for the light chain and heavy chain variable regions can then be isolated using the polymerase chain reaction and appropriately selected primers. See, Orlandi et al., Proc. Natl. Acad. Sci., U.S.A., 86:3833 (1989) and Huse et al., Science, 246:1275 (1989). The variable regions are then inserted into plant expression vectors, such as the expression vectors described by Hiatt et al., Nature, 342:76-78 (1989).

In a preferred embodiment, the biologically active glycopolypeptide multimer is a immunoglobulin immunospecific for an intestinal pathogen antigen. Particularly preferred are immunoglobulins immunospecific for intestinal pathogens such as bacteria, viruses, and parasites that cause disease in the gastrointestinal tract, such as E. coli,

Salmonellae, Vibrio cholerae, Salm nellae typhimurium, and Streptococcus mutans. Also contemplated by the present invention are glycopolypeptide multimers that are immunoglobulins immunospecific for Diphtheria toxin, such as the antibody produced by the hybridoma ATCC No. HB 8329; antibodies immunospecific Pseudomonas aeruginosa exotoxin A, such as the antibody produced by the hybridoma D253-15-6 (ATCC No. H 8789); immunoglobulins immunospecific for Ricin A or B chain, such as the immunoglobulins produced by hybridomas TFT A1 (ATCC No. CRL 1771) or TFTB1 (ATCC No. 1759); immunoglobulins immunospecific for Schistosoma mansoni glycoprotein, such as the antibody produced by hybridoma 130 C/2B/8 (ATCC No. 8088); immunoglobulins immunospecific for Shigella SHIGA toxin and Shigella-like toxin, such as the antibodies produced by hybridoma 13C4 (ATCC No. 1794); immunoglobulins immunospecific for tetanus toxoid, such as the immunoglobulins produced by hybridomas 9F12 (ATCC No. HB8177) and hybridoma SA13 (ATCC No. HB8501); immunoglobulins immunospecific for Trichinella spiralis, such as hybridoma 7C₂C₅C₁₂ (ATCC No. HB 8678); immunoglobulins immunospecific for Dengue viruses or complexes, such as the immunoglobulins produced by D3-2H2-9-21 (ATCC No. HB 114), hybridoma 15F3-1 (ATCC No. HB 47), hybridoma 3H5-1 (ATCC No. HB 46), hybridoma 5D4-11 (ATCC No. HB 49), hybridoma 1H10-6 (ATCC No. HB 48); immunoglobulins immunospecific for Hepatitis B surface antigen, such as hybridoma H25B10 (ATCC No. CRL 8017), hybridoma H21F8-1 (ATCC No. CRL 8018); immunoglobulins immunospecific for Herpes simplex viruses, such as the immunoglobulin produced by hybridoma 1D4 (ATCC No. HB 8068), hybridoma 39-S (ATCC No. HB 8180), hybridoma 52-S (ATCC No. HB 8181), hybridoma 3N1 (ATCC No. HB

8067); immunoglobulins immunospecific for influenza virus, such as the immunoglobulins produced by HK-PEG-1 (ATCC No. CL 189), hybridoma M2-1C6-4R3 (ATCC No. HB64); immunoglobulins immunospecific for
5 parainfluenza virus, such as the immunoglobulin produced by hybridoma 9-3-4 (ATCC No. 8935); and immunoglobulins immunospecific for parvoviruses, such as the immunoglobulin produced by 3C9-D11-H11 (ATCC No. CRL 1745).

10 In other preferred embodiments, the glycopolypeptide multimer present in the composition is an immunoglobulin molecule that is immunospecific for a dental pathogen antigen such as Streptococcus mutans and the like. Particularly preferred are
15 immunoglobulins immunospecific for a Streptococcus mutans antigen such as the immunoglobulin produced by hybridoma 15B2 (ATCC No. HB 8510).

The present invention contemplates producing passive immunity in an animal, such as a vertebrate.
20 In preferred embodiments, passive immunity is produced in fish, birds, reptiles, amphibians, or insects. In other preferred embodiments passive is produced in a mammal, such as a human, a domestic animal, such as a ruminant, a cow, a pig, a horse, a dog, a cat, and the
25 like. In particularly preferred embodiments, passive immunity is produced in an adult mammal.

In preferred embodiments, passive immunity is produced in an animal, such as a mammal that is weaned and therefore no longer nurses to obtain milk from its
30 mother. Passive immunity is produced in such an animal by administering to the animal a sufficient amount of a composition containing a glycopolypeptide multimer immunospecific for a preselected ligand to produce a prophylactic concentration of the
35 glycopolypeptide multimer within the animal. A

prophylactic concentration of a glycopolypeptide multimer, such as an immunoglobulin is an amount sufficient to bind to a pathogen present and prevent that pathogen from causing detectable disease within the animal. The amount of composition containing the glycopolypeptide multimer required to produce a prophylactic concentrations will vary as is well known in the art with the size of the animal, the amount of pathogen present, the affinity of the particular glycopolypeptide multimer for the pathogen, the efficiency with which the particular glycopolypeptide multimer is delivered to its active location within the animal, and the like.

The present invention also contemplates a method for providing passive immunity against a pathogen to an animal, by administering to the animal an encapsulated, biologically active glycopolypeptide multimer capable of binding a pathogen antigen in an amount sufficient to establish within the animal a prophylactic concentration of the multimer that contains a polypeptide having a glycosylated core portion as well as N-acetylglucosamine containing outer branches and an amino acid residue sequence of an immunoglobulin molecule and where the multimer is free from detectable sialic acid residues.

In preferred embodiments, the biologically active glycopolypeptide multimer is encapsulated in a protective coating. The encapsulation material may be a membrane, a gel, a polymer or the like. The encapsulation material functions to protect the material it contains and to control the flow of material in and out of the encapsulation device. In preferred embodiments, the glycopolypeptide multimer is encapsulated within a plant cell wall, a plant cell, a micelle, an enteric coating, and the like.

In preferred embodiments, glycopolypeptide multimers, such as, tissue plasminogen activator, recombinant human insulin, recombinant alpha interferon and growth hormone, have been successfully administered and are therapeutically effective through buccal, nasal, and rectal mucosa using various approaches. Epstein et al., Alternative Delivery Systems for Peptides and Proteins as Drugs, CRC Critical. Rev. in Therapeutic Drug Carrier Systems, 5:99-139 (1988).

In preferred embodiments, the biologically active glycopolypeptide multimer is administered by intranasal formulations in solution. The formulation is administered by one of three ways: a single dose through a catheter; multiple doses through metered dose pumps (also called nebulizers); and multiple doses through the use of metered dose pressurized aerosols. If desired, the absorption of the peptide or protein across the nasal mucosa, may be promoted by adding absorption enhancers including nonionic polyoxyethylene ethers, bile salts such as sodium glycocholate (SGC) and deoxycholate (DOC), and derivative of fusidic acid such as sodium taurodi hydrofusidate (STDHF).

Nasal insulin formulations containing 0.9% weight per volume of sodium chloride and 1% DOC, 0.5 U/kg of insulin administered as a spray using a metered dose spray pump resulted in rapid elevations of serum insulin. Moses et al., Diabetes 32:1040 (1983). Dosages of biologically active glycopolypeptide multimers can range from 0.15 mg/kg up to 600 mg/kg, preferred dosages range from 0.15 mg/ml up to 200 mg/kg, and most preferred dosages range from 1 mg/kg up to 200 mg/kg in a nasal spray formulation. In preferred embodiments, the multimer

do s not cross the mucosal membrane and thus
absorption enhancers ar not required. Several dosage
forms are available for the r ctal delivery of
biologically active glycopolypeptide multimers. These
5 include suppositories (emulsion and suspension types),
rectal gelatin capsules (solutions and suspensions),
and enemas (macro: 100 milliliters (ml) or more; and
micro: 1 to 20 ml). Osmotic pumps designed to
deliver a volume of 2 ml in a 24 to 40 hour period
10 have also been developed for rectal delivery.
Absorption enhancers described for nasal formulations
are included in the formulations if increased
transport across rectal mucosa is desired. A
preferred formulation for rectal administration of the
15 biologically active glycopolypeptide multimer consists
of the preferred ranges listed above in any one of the
acceptable dosage forms.

Biologically active glycopolypeptide multimers
can be administered in a liposome (micelle)
20 formulation which can be administered by application
to mucous membranes of body cavities. Juliano et al.,
J. Pharmacol. Exp. Ther., 214:381 (1980). Liposomes
are prepared by a variety of techniques well known to
those skilled in the art to yield several different
25 physical structures, ranging from the smallest
unilammelar vesicles of approximately 20 to 50
nanometers in diameter up to multilamellar vesicles of
tens of microns in diameter. Gregoriadiaz, Ed.,
Liposome Technology, 1:Crc Press (1984). The
30 biologically active glycopolypeptide multimers in the
preferred dosages listed for nasal formulations are
hydrated with a lyophilized powder of multilammelar
vesicles to form glycopolypeptide containing-
liposomes.

In a more preferred embodiment, biologically active glycopolypeptide multimers in the above mentioned preferred dosages are orally administered in gelatin capsules which are coated with an azoaromatic cross-linked polymer. The azopolymer-coated glycopolypeptide is protected from digestion in the stomach and the small intestine. When the azopolymer-coated glycopolypeptide reaches the large intestine, the indigenous microflora reduce the azo bonds, break the cross-links, and degrade the polymer film. This results in the release of the glycopolypeptide multimers into the lumen of the colon for subsequent local action or absorption.

Preferably, the pathogen specific glycopolypeptide multimer is administered in an amount sufficient to establish a prophylactic concentration of the multimer at a particular location in the animal. The amount of multimer that is administered to produce a particular prophylactic concentration will vary, as is well known in the art, with the amount of pathogen present, the exact location in the animal desired to be immunized, the affinity of the multimer for the pathogen, the resistance of the multimer to denaturation or degradation, the mode of pathogen inactivation, the dosage formulation and the like.

Preferably, the multimer is administered in 10 g to 100,000 g of plant material containing about 0.1 mg to 2,000 mg of multimer in 1 to 4 separate doses each day. This amount of multimer produces a prophylactic concentration of about 0.01 mg/kg of body weight to about 2,000 mg/kg of body weight. In preferred embodiments, the prophylactic concentration of multimer is from about 0.01 mg/kg of body weight to about 600 mg/kg of body weight. In the preferred

embodiments, the prophylactic concentration is from about 0.01 mg/kg body weight to about 200 mg/kg of body weight.

5 The present invention contemplates a method for providing passive immunity to an animal against a preselected ligand, which method comprises administering to the animal biologically active glycopolypeptide multimers capable of binding a preselected ligand in an amount sufficient to
10 establish within the animal a prophylactic concentration of the multimer. The multimer administered comprises a polypeptide having a glycosylated core portion as well as N-acetylglucosamine-containing outer branches and an
15 amino acid sequence of an immunoglobulin molecule, such that the multimer is free from detectable sialic acid residues.

Particularly preferred, is a method for providing passive immunity to an animal against a
20 pathogen, which method comprises administering to the animal a biologically active glycopolypeptide multimer capable of binding a pathogen in amounts sufficient to establish within the animal a prophylactic concentration of the multimer. The multimer
25 administered comprises a polypeptide having a glycosylated core portion as well as N-acetylglucosamine-containing outer branches and an amino acid residue sequence of an immunoglobulin molecule, such that the multimer is free from
30 detectable sialic acid residues.

In preferred embodiments, the multimer is administered as a composition constituted by the multimer and a material having nutritional value. A material having nutritional value is a substance or
35 compound from which the animal can derive calories.

Typical materials having nutritional value include proteins, carbohydrates, lipids, fats, glycoproteins, glycogen, and the like. Particularly preferred are materials having nutritional value that are plant materials or animal materials.

In other preferred embodiments, the multimer is administered as a composition constituted by the multimer and a physiologically inert material. Physiologically inert materials include solutions such as water and carrier compounds.

In other preferred embodiments, a method of passively immunizing an animal against a preselected ligand comprising introducing into the gastrointestinal tract of an animal a composition comprising plant cell walls and a biologically active glycopolyptide multimer that is capable of binding a preselected antigen; said glycopolyptide multimer comprising at least two polypeptides, one of said polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a core portion and a N-acetylglucosamine-containing outer branches, said multimer being free from sialic acid residues.

Other preferred embodiments contemplate a method of passively immunizing an animal against a preselected antigen, comprising:

(1) introducing into the gastrointestinal tract of an animal a composition comprising plant cells containing a biologically active glycopolyptide multimer that is capable binding a preselected ligand; said multimer comprising at least two polypeptides, one of said polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a core portion and a N-acetylglucosamine-containing outer

branches, such that the multimer is free from sialic acid residues; and

(2) disrupting the plant cell within the gastrointestinal tract, thereby releasing the biologically active glycopolypeptide multimer into the gastrointestinal tract, and passively immunizing the animal.

D. Compositions Containing Glycopolypeptide Multimer

The present invention also contemplates biologically active compositions which comprise an encapsulated glycopolypeptide multimer comprising at least two polypeptides, one of said polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a core portion and a N-acetylglucosamine-containing outer branches, such that the multimer is free from sialic acid residues.

In preferred embodiments the glycopolypeptide multimer is encapsulated in a plant cell, a plant cell wall, an enteric coating, a coating, and the like.

Particularly preferred are compositions containing ratios of about 10,000 grams of plant material to each 100 nanograms of glycopolypeptide multimer present to ratios of about 100 nanograms of plant material for each 10 grams of glycopolypeptide multimer present in the composition. In more preferred embodiments, the plant material is present in a ratio from about 10,000 grams of plant material for each one milligram of glycopolypeptide multimer present, to a ratio of about 100 nanograms of plant material present for each gram of glycopolypeptide multimer present. In other preferred embodiments, the plant material is present in a ratio from about 10,000

grams of plant material for each milligram of
glycopolypeptide multimer present to about one
milligram of plant material present for each 500
milligrams of glycopolypeptide multimer present in the
composition.

In other embodiments, the composition further
comprises chlorophyll, synergistic compounds,
medicines, compounds derived from medicinal plants,
and various pharmaceuticals and the like. Compounds
from a medicinal plant may be added to the composition
by expressing the glycopolypeptide multimer in the
medicinal plant and then harvesting the plant.

The present invention also contemplates a
glycopolypeptide multimer produced according to the
method comprising:

(a) introducing into the genome of a
first member of the plant species a first mammalian
gene coding for an autogenously linking monomeric
polypeptide having a N-linked glycosylation signal
that is a constituent part of the glycopolypeptide
multimer to produce a first transformant;

(b) introducing into the genome of a
second member of the same plant species another
mammalian gene coding for another autogenously linking
monomeric polypeptide that is a constituent part of
the glycopolypeptide multimer to produce a second
transformant;

(c) generating from said first and
second transformants a progeny population; and

(d) isolating from said progeny
population a transgenic plant species that produces
the glycopolypeptide multimer.

Other multimers produced by the methods of
this invention are contemplated.

Examples

The following examples are intended to illustrate, but not limit, the scope of the invention.

1. Isolation Of An Immunoglobulin Heavy Chain-Coding Gene And An Immunoglobulin Light Chain-Coding Gene From The Hybridoma Cell Line 6D4

Hybridoma cells secreting the 6D4 antibody described by Tramontano et al., Science, 234:1566-1570 (1986) were grown to log phase in DMEM medium supplemented with 10% fetal calf serum. Total RNA was prepared from 2 liters of log phase 6D4 hybridoma cells using the methods described by Ullrich et al., Science, 196:1313 (1977). Briefly, the 6D4 cells were collected by centrifugation and homogenized at room temperature for 20 seconds in 70 ml of 4 M guanidinium thiocyanate containing 5 mM sodium citrate at pH 7.0, 0.1 M 2-mercaptoethanol (2Me) and 0.5% sodium lauryl sacosinate using a Polytron homogenizer. The homogenate was centrifuged briefly for 5 minutes at 8,000 x g to remove the insoluble debris.

About 28 ml of homogenate was layered onto a 10 ml pad of 5.7 M CsCl (Bethesda Research Laboratories, Gaithersburg, MD) in 4 mM ethylene diamine tetra acetic acid (EDTA) at pH 7.5 in a Beckman SW70 Ti rotor. The solution was centrifuged for at least 5 hours at 50,000 revolutions per minute (rpm) at 15C. The supernatant was carefully aspirated and the walls of the tubes dried to remove any remaining homogenate. The RNA pellet was dissolved in a solution containing 10 mM Tris-HCl at pH 7.4, 2 mM EDTA and 0.5% sodium dodecyl sulfate (SDS). This solution was extracted twice with a phenol solution. The resulting aqueous phase was reextracted with solution containing Phenol:chloroform:isoamyl alcohol

(25:25:1 by volume). The RNA was recovered from the resulting aqueous phase by adding 1/10 volume of 3 M sodium acetate and 2 volumes of ethanol. This solution was maintained at -20C for 12 to 18 hours to precipitate the RNA. The solution containing the precipitated RNA was centrifuged for 20 minutes at 10,000 x g at 4C to produce a RNA containing pellet. The excess salt was removed from the RNA pellet by admixing 5 ml of 70% ethanol to the RNA pellet and the solution was centrifuged for 10 minutes at 10,000 x g at 4C. The final RNA pellet was dissolved in 0.5 ml of DEPC-H₂O and stored at -70C after removing a small aliquot to determine the RNA concentration by absorbance at 260 nm.

Messenger RNA (mRNA) enriched for sequences containing long poly A tracts was prepared from the total cellular RNA using the methods described in Molecular Cloning: A Laboratory Manual, Maniatis et al., eds., Cold Spring Harbor Laboratory, NY (1982). Briefly, the total RNA prepared above was resuspended in one ml of DEPC-H₂O and maintained at 65C for five minutes. One ml of 2x high salt loading buffer consisting of 100 mM Tris-Cl, 1 M sodium chloride (NaCl), 2.0 mM EDTA at pH 7.5, and 1.0% sodium dodecyl sulfate (SDS) was added to the resuspended RNA and the mixture allowed to cool to room temperature. The mixture was then applied to an oligo-dT (Collaborative Research Type 2 or Type 3) column that had been previously prepared by washing the oligo-dT with a solution containing 0.1 M sodium hydroxide and 5 mM EDTA and then equilibrating the column with DEPC-H₂O. The eluate was collected in a sterile polypropylene tube and reapplied to the same column after heating the eluate for 5 minutes at 65C. The oligo dT column was then washed with 20 ml of high salt loading buffer

consisting of 50 mM Tris-Cl at pH 7.5, 500 mM NaCl, 1 mM EDTA at pH 7.5 and 0.5% SDS. The messenger RNA was eluted from the oligo dT column with 1 ml f buffer consisting of 10 mM Tris-Cl at pH 7.5, 1 mM EDTA at pH 7.5 and 0.05% SDS. The messenger RNA was concentrated by ethanol precipitation and resuspended in DEPC H₂O.

Complementary DNA (cDNA) was prepared from the mRNA prepared above. The first strand synthesis, second strand synthesis, and the fill-in reactions were carried out according to the procedures described by Watson et al., DNA Cloning Volume I, D.M. Glover, ed. Briefly, a solution containing 10 ug of mRNA was maintained at 65C for 5 minutes and then quickly chilled on ice. The first cDNA strand was synthesized by admixing to this solution 100 ul of a reaction mixture containing 50 mM Tris-Cl at pH 8.3, 8 mM MgCl₂, 50 mM KCl, 2 ug oligo (dT) 1 mM dATP, 1 mM dGTP, 1 mM dTTP, 1 mM dCTP, 10 mM DTT, 60 units of RNasin (Promega Corporation, Madison, WI), 4 ug Actinomycin, 135 units of AMV reverse transcriptase and 10 uCi $\alpha^{32}\text{P}$ -dCTP. This reaction mixture was maintained at 44C for 1 hour. An additional 60 units of RNasin and 80 units of reverse transcriptase were added and the reaction mixture maintained at 44C for 30 minutes. The first strand cDNA synthesis reaction was terminated by adding .005 ml of a solution containing 50 mM EDTA and 10% SDS. The nucleic acids were purified by phenol extraction and then concentrated by ethanol precipitation.

The second strand cDNA was synthesized by admixing all of the first strand cDNA product produced above to a 100 ul solution containing 20 mM Tris-Cl at pH 7.5, 100 mM KCl, 5 mM MgCl₂, 10 mM (NH₂)₂ SO₄, 10 mM DTT, 0.05 mg/ml bovine serum albumin (BSA), 50 uM of dGTP, 50 uM dATP, 50 uM dTTP, 50 uM dCTP, 150 uM b ta-

nicotinamide adenine dinucleotide (β -NAD⁺) (Sigma Chemical Company, St. Louis, MO), 15 uCi/ul [α -³²P]dCTP, 30 units E. coli DNA polymerase, 2.5 units RNase H, and 4 units E. coli DNA ligase. This
5 solution was maintained at 14C for 1 hour and then further maintained at 25C for 1 hour. The second strand cDNA synthesis reaction was terminated by adding 5 ul of 0.05 M EDTA at pH 8.0, 5 ul of 10% SDS. The nucleic acids were purified from this reaction
10 mixture by phenol extraction followed by ethanol precipitation.

The double stranded cDNA produced above was prepared for insertion into a cloning vector, by
15 converting the ends of the double stranded cDNA to blunt ends in the following fill-in reaction. One half of the double stranded cDNA produced above was added to a solution containing 33.4 mM Tris-acetate at pH 7.8, 66.6 mM potassium acetate, 10 mM magnesium acetate, 0.5 mM DTT 87.5 ug/ml BSA, 310 uM dGTP, 310
20 uM dATP, 310 uM dTTP, 310 uM dCTP and 8 units of T4 DNA polymerase. This solution was maintained at 37C for 30 minutes and the reaction terminated by adding 5 ul of 0.05 M EDTA. The blunt-ended, cDNA produced was purified by phenol extraction and ethanol
25 precipitation.

Eco RI adaptors were annealed and then ligated to the blunt-ended cDNA produced above. Briefly, polynucleotide N1 (Table 1) was kinased by adding 1 ul of the polynucleotide and 20 units of T4
30 polynucleotide kinase to a solution containing 70 mM Tris-Cl at pH 7.6, 10 mM MgCl₂, 5 mM DTT, 10 mM 2Me and 500 ug/ml of BSA. The solution was maintained at 37C for 30 minutes and the reaction stopped by maintaining the solution at 65C for 10 minutes. 20 ng
35 of polynucleotide N2 (Table 1) was added to the above

kinasing reaction together with 1/10 volume of a solution containing 20 mM Tris-Cl at pH 7.4, 2 mM MgCl₂ and 15 mM NaCl. This solution was heated to 70C for 5 minutes and allowed to cool to room temperature, approximately 25C, over 1.5 hours in a 500 ul beaker of water. During this time period, the 2 polynucleotides present in the solution annealed to form the double stranded Eco RI adaptor.

10

Table 1Eco RI Adaptor Polynucleotides

(N1) 5'-CCTTGACCGTAAGACATG-3'

(N2) 5'-AATTCATGTCTTACGGTCAAGG-3'

15

This double stranded Eco RI adaptor was covalently linked (ligated) to the blunt-ended cDNA produced above by adding 5 ul of the annealed adaptors to a solution containing 50 ul Tris-Cl at pH 7.5, 7 ul MgCl₂, 1 mM DTT, 1 mM ATP and 10 units of T4 DNA ligase. This solution was maintained at 37C for 30 minutes and then the T4 DNA ligase was inactivated by maintaining a solution at 72C for 15 minutes.

20

25

The 5' ends of the resulting cDNA were phosphorylated by admixing 5 ul of the above reaction, 4 ul of a solution containing 10 mM ATP and 5 units of T4 polynucleotide kinase. This solution was maintained at 37C for 30 minutes and then the T4 polynucleotide kinase was inactivated by maintaining the solution at 65C for 10 minutes.

30

35

The cDNA prepared above was size fractionated to obtain long cDNA inserts using a method similar to the method described in Molecular Cloning: A Laboratory Manual, Maniatis et al., eds., Cold Spring Harbor Laboratory, NY (1982). Briefly, the reaction mixture prepared above was added to an equal volume of

2x CL4B column buffer consisting of 20 mM Tris-Cl at pH 8.0, 1.2 M NaCl, 1 mM EDTA and 0.1% sarkosyl. This solution was loaded onto a 5 ml CL-4B column that was previously prepared using pre-swollen sepharose CL-4B (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). The sample was allowed to enter the column and then the column was filled with 1x column buffer consisting of 10 mM Tris-Cl at pH 8.0, 600 mM NaCl, 1 mM EDTA and 0.1% sarkosyl. The column was allowed to flow by gravity and approximately 200 ul fractions were collected manually. The size of the double stranded cDNA present in each of the fractions was determined by gel electrophoresis through a 0.8% agarose gel. Fractions containing high molecular weight cDNA as determined by the agarose gel electrophoreses were pooled and concentrated using butanol extraction and then ethanol precipitated to produce size-fractionated cDNA.

The size-fractionated cDNA prepared above was ligated directly into lambda Zap (Stratagene Cloning Systems, La Jolla, CA) that had been previously digested with the restriction endonuclease Eco RI. The ligation mixture was packaged according to the manufacturers' instructions using Gigapack II gold packaging extract available from Stratagene Cloning Systems and plated on BB4 cells (Stratagene Cloning Systems, La Jolla, CA) to produce plaques.

The plaques were screened with a radiolabeled probe containing the constant region gene of a human antibody. Briefly, the human Ig^G constant region probe previously described by Rabbitts et al., Cold Spring Harbor Quantitative Biology 45:867-878 (1980), and the human Kappa light chain probe previously described by Rabbitts et al., Cold Spring Harbor Quantitative Biology 45:867-878 (1980), was nick

translated using standard protocols described by
Molecular Cloning: A Laboratory Manual, Maniatis et
al., ds., Cold Spring Harbor, NY (1982). Probes
prepared using this protocol and having a specific
5 activity of greater than 1×10^8 cpm/ug were
hybridized with plaques from the above-prepared
library using methods well known to one skilled in the
art. Briefly, the titer of the cDNA library prepared
above was determined by making serial dilutions of the
10 library into a buffer containing 100 mM NaCl, 50 mM
Tris-Cl at pH 7.5 and 10 mM magnesium sulfate. 10 ul
of each dilution was admixed to 200 ul of
exponentially growing E. coli cells and maintained at
37C for 15 minutes to allow the phage to absorb to the
15 bacterial cells. 3 ml of top agar consisting of 5 g/l
NaCl, 2 g/l of magnesium sulfate, 5 g/l of yeast
extract, 10 g/l of NZ Amine (casein hydrolysate) and
0.7% molten agarose was prepared and placed in a 50C
water bath until used. The phage, the bacteria and
20 the top agar were mixed and then evenly distributed
across the surface of a prewarmed bacterial agar plate
(5 g/l NaCl, 2 g/l magnesium sulfate, 5 g/l yeast
extract, 10 g/l NZ Amine and 15 g/l difco agar. The
plates were maintained at 37C for 12 to 24 hours
25 during which time the lambda plaques developed on the
bacterial lawn. The lambda plaques were counted to
determine the total number of plaque forming units per
milliliter in the original library.

The titered cDNA library was then plated out
30 so that replica filters could be produced from the
library. The replica filters were used to later
segregate the individual clones containing cDNAs
coding for either immunoglobulin heavy or
immunoglobulin light chain. Briefly, a volume of the
35 titer cDNA library that would yield 20,000 plaques per

150 millimeter plate was added to 600 ul of exponentially growing E. coli cells and maintained at 37C for 15 minutes to allow the phage to absorb to the bacterial cells. Then 7.5 ml of top agar was added to the solution containing the bacterial cells and phage. The bacterial cells with the phage absorbed to them were mixed with the top agar and the entire mixture distributed evenly across the surface of the pre-warmed bacterial agar plate. This entire process was repeated for sufficient number of plates to produce a total number of plaques at least equal to the library size. These plates were then maintained at 37C for 16 hours during which time the plaques appeared on the bacterial lawn. The plates were then overlaid with nitrocellulose filters and the orientation of each filter on the bacterial plates marked with ink dots. The filters were maintained on the bacterial plates for 1 to 5 minutes and then removed with a blunt-ended forceps and placed contact side up on a sponge pad soaked in a denaturing solution consisting of 1.5 M NaCl and 0.5 M NaOH for approximately 1 minute. The filter was then transferred, contact side up, onto a sponge pad containing a neutralizing solution consisting of 1.5 M NaCl and 0.5 M Tris-Cl at pH 8.0 for 5 minutes. The filter was then rinsed in a solution containing 0.36 M NaCl, 20 mM NaH_2PO_4 at pH 7.4, and 2 mM EDTA and placed on Whatman 3 MM paper to dry. This process was repeated for each bacterial plate to produce a second replica filter for hybridization. After all the filters were dry the sheets were placed between Whatman 3 MM paper and the filter was baked for 2 hours at 80C in a vacuum oven. The filters were now ready for hybridization with specific probes.

The baked filters were placed on the surface of a solution containing 0.9 M NaCl and 0.09 M sodium citrate at pH 7.0 until they have become thoroughly wetted from beneath. The filters were submerged in the same solution for 5 minutes. The filters were transferred to a pre-washing solution containing 50 mM Tris-Cl at pH 8.0, 1 M NaCl, 1 mM EDTA and 0.1% SDS. The pre-washing solution was then maintained at 42C for 2 hours.

The filters were removed from the pre-washing solution and placed in a pre-hybridization solution containing 25% formamide, 1.0 M NaCl 50% dextran sulfate, 0.05 M NaPO₄ at pH 7.7, 0.005 M EDTA, 0.1% ficoll, 0.1% BSA, 0.1% poly(vinyl pyrrolidone), 0.1% SDS and 100 ug/ml denatured, salmon sperm DNA. The filters were maintained in the pre-hybridization solution for 4 to 6 hours at 42C with gentle mixing. The filters are then removed from the pre-hybridization solution and placed in a hybridization solution consisting of pre-hybridization solution containing 2×10^6 cpm/ml of ³²P-labeled probe that has a specific activity of at least 1×10^8 cpm/ug. The filters were maintained in the hybridization solution for 12 to 24 hours at 42C with gentle mixing. After the hybridization was complete the hybridization solution is discarded and the filters were washed 3 to 4 times for 10 minutes in a large volume of a solution containing 0.9 M NaCl, 0.09 M sodium citrate at pH 7.0 and 0.1% SDS at 60C. The filters were removed from the washing solution and air dried on a sheet of Whatman 3 MM paper at room temperature. The filters were taped to sheets of 3 MM paper and wrapped with plastic wrap and used to expose X-ray film (Kodak XR or equivalent) at -70C with an intensifying screen to produce an autoradiogram. The film was developed

according to manufacturers' directions. Positive hybridization signals were aligned to the proper plaque by virtue of the asymmetrical ink spots placed on the nitrocellulose filters.

5 Hybridizing plaques were isolated to purity and the inserts excised from the lambda ZAP vector according to the underlying in vivo excision protocol provided by the manufacturer; Stratagene Cloning Systems, La Jolla, CA and described in Short et al.,
10 Nucleic Acids Res., 16:7583-7600 (1988). This in vivo excision protocol moves the cloned insert from the lambda ZAP vector into a phagemid vector to allow easy manipulation and sequencing. The hybridizing inserts were sequenced using the Sanger dideoxide method
15 described by Sanger et al., Proc. Natl. Acad. Sci. USA, 74:5463-5467 (1977) and using the Sequenase DNA Sequencing kit (United States Biochemical Corporation, Cleveland, OH). Two full length light chain clones designated pABZ100 and pABZ101 were identified by DNA
20 sequencing. In addition, one full length heavy chain clone designated pABZ200 was also identified.

 These full length cDNA clones were subcloned into mp18 using procedures similar to the procedures described in Molecular Cloning: A Laboratory Manual,
25 Maniatis et al., eds., Cold Spring Harbor Laboratory NY (1982). Briefly, the phagemids containing the full length cDNA clones were digested with the restriction endonuclease Eco RI and the full length cDNA inserts isolated by gel electrophoresis. The isolated full
30 length cDNA inserts were ligated to M13 mp18 that had been previously digested with Eco RI. The ligation mixture was plated on appropriate bacterial host cells and phage plaques containing the full length cDNA inserts isolated. The accuracy of this cloning step
35 was confirmed by restriction mapping.

Single stranded uracil-containing template DNA was prepared according to the protocols provided with the Muta-Gene M13 in vitro Mutagenesis kit (Bio-Rad Laboratories, Richmond, CA). Briefly, an isolated colony of bacterial strain CJ236 containing both the dut and ung mutations was admixed into 20 ml of LB media (10 g/l Bactotryptone, 5 g/l yeast extract and 5 g/l NaCl) containing 30 ug/ml chloramphenicol. This solution was maintained at 37C for 12 to 16 hours to produce an overnight culture. 1 ml of this overnight culture was admixed with 50 ml of 2x YT medium (16 g/l Bactotryptone, 10 g/l yeast extract and 5 g/l NaCl) containing 30 ug/ml chloramphenicol in a 250 ml flask. This solution was maintained at 37C with constant shaking for about 4 hours or until the optical density at 600 nanometers (nm) was 0.3. This optical density corresponds to approximately 1×10^7 colony forming units per millimeter. The M13 phage containing the full length cDNA inserts were added at a multiplicity of infection of 0.2 or less. This solution was maintained with shaking at 37C for 4 to 6 hours. 30 ml of the resulting culture was transferred to a 50 ml centrifuge tube and centrifuged at 17,000 x g (12,000 revolutions per minute in the Sorvall SS-34 rotor) for 15 minutes at 4C. The resulting phage particle containing supernatant was transferred to a fresh centrifuge tube and recentrifuged at 17,000 x g for 15 minutes at 4C. This second supernatant was transferred to a fresh polyallomer centrifuge tube and 150 micrograms of RNase A admixed to the supernatant. This supernatant was maintained at room temperature for 30 minutes to allow the RNase A to digest any RNA present. One-fourth volume of a solution containing 3.5 M ammonium acetate and 20% polyethylene glycol 8000 (PEG 8000) was admixed to this supernatant. This

supernatant was maintained on ice for 30 minutes. During this time, any phage particles present in the supernatant were precipitated by the PEG 8000. The precipitated phage particles were collected by
5 centrifuging this solution at 17,000 x g for 15 minutes at 4C. The resulting pellet was resuspended in 200 ul of high salt buffer (300 mM NaCl, 100 mM Tris-Cl at pH 8.0 and 1 mM EDTA). This solution was maintained on ice for 30 minutes and then centrifuged
10 for 2 minutes in a microfuge to remove any insoluble material. The resulting supernatant was transferred to a fresh tube and stored at 4C until used as a phage stock.

Single stranded uracil containing template DNA
15 was prepared by extracting the entire 200 ul phage stock twice with an equal volume of neutralized phenol. The aqueous phase was re-extracted once with a solution of phenol chloroform (25:25:1 phenol: chloroform:isoamyl alcohol) and further extracted
20 several times with chloroform isoamyl alcohol (1:1/48 chloroform:isoamyl alcohol). One/tenth volume of 7.8 M ammonium acetate and 2.5 volumes of ethanol were admixed to the resulting aqueous phase. This solution was maintained at -70C for at least 30 minutes to
25 precipitate the DNA. The precipitated DNA was collected by centrifuging the solution for 15 minutes at 4C. The resulting DNA pellet was washed once with 90% ethanol and resuspended in 20 ul of a solution containing 10 mM Tris-Cl at pH 7.6 and 1 M EDTA. The
30 amount of uracil containing template DNA present in this solution was determined by gel electrophoresis. This uracil containing template DNA was used in further mutagenesis steps to introduce restriction endonuclease sites into the full length cDNAs.

Mutagenic full length cDNAs were synth sized according to the procedures provided in the Muta-G n kit (Bio-Rad Laboratories, Richmond, CA). Bri fly, polynucleotides designed to introduce Eco RI
5 restriction endonuclease sites were used to prime the synthesis of a mutagenic strand from the single-stranded uracil containing template DNA. The polynucleotide was phosphorylated by admixing 200 picomoles (pmoles) of the selected polynucleotide with
10 a solution containing 100 mM Tris-Cl at pH 8.0, 10 mM MgCl₂, 5 mM DTT, 0.4 mM ATP and 4.5 units of T4 polynucleotide kinase to produce a kinasing reaction. This solution was maintained at 37C for 45 minutes. The kinasing reaction was stopped by maintaining the
15 solution at 65C for 10 minutes. The kinased polynucleotide was diluted to 6 moles/ul with a solution containing 10 mM Tris-Cl at pH 7.6 and 1 mM EDTA.

The kinased polynucleotide was annealed to the
20 single stranded uracil containing DNA template prepared above by admixing 200 ng of uracil containing template DNA, 3 moles of kinased polynucleotide, 20 mM Tris-Cl at pH 7.4, 2 mM MgCl₂ and 50 mM NaCl. This solution was maintained at 70C for 5 minutes and
25 allowed to cool at a rate of approximately 1C per minute to 30C. This solution was then maintained on ice until used. 1 ul of a solution containing 4 mM dATP, 4 mM dCTP, 4 mM dCTP, 4 mM TTP, 7.5 mM ATP, 175 mM Tris-Cl at pH 7.4, 37.5 mM MgCl₂, 215 mM DTT, was
30 admixed to the solution along with 5 units of T4 DNA ligase and 1 unit of 4 DNA polymerase. This solution was maintained on ice for 5 minutes to stabilize the polynucleotide primer by initiation of DNA synthesis under conditions that favor binding of the
35 polynucleotide to the uracil containing template. The

solution was then maintained at 25C for 5 minutes and finally maintained at 37C for 90 minutes. The synthesis reaction was stopped by admixing 90 ul of stop buffer (10 mM Tris-Cl at pH 8.0 and 10 mM EDTA) to this solution and freezing it. This synthesis reaction was then stored at -20C until used.

The synthesis reaction was transformed into competent MV1190 cells using the protocol described in the Muta-Gene kit. Briefly, competent MV1190 cells were prepared by admixing an isolated colony of MV1190 cells to 10 ml of LB medium and maintaining this solution at 37C overnight with constant shaking. The next day, 40 ml of LB medium was admixed with a sufficient amount of the overnight MV1190 culture to give an initial absorbance reading (optical density at 600 nm) of approximately 0.1. The solution was then maintained at 37C for approximately 2 hours with constant shaking. During this time, the culture should reach an absorbance reading of 0.8 to 0.9. When this absorbance reading is reached, the MV1190 cells were centrifuged at 5,000 rpm for 5 minutes at 0C. The MV1190 cell pellet was resuspended in 1 ml of ice-cold 50 mM CaCl₂. An additional 19 ml of ice-cold 50 mM CaCl₂ was admixed to this solution. The resulting solution was maintained on ice for 30 minutes. The cells were centrifuged at 5,000 rpm for 5 minutes at 0C. The MV1190 cell pellet was resuspended in 1 ml of ice-cold 50 mM CaCl₂. An additional 3 ml of ice-cold 50 mM CaCl₂ was admixed to the solution and the solution maintained on ice. The MV1190 cells were now competent for transformation.

A 10 ul aliquot of the synthesis reaction prepared above was admixed gently with 0.3 ml of competent MV1190 cells in a cold 1.5 ml sterile polypropylene tube. This solution was maintained on

ice for 90 minutes. The solution was then placed in a 42C water bath for 3 minutes and r turned imm diately to ice. Th transformed cells were then plated on th MV1190 cell line at 3 different concentrations. 10
5 ul, 50 ul, and 100 ul of the transformed cells were added to individual tubes containing 0.3 ml of a MV1190 overnight cell culture. This solution was gently but thoroughly mixed and then 50 ul of 2% 5-bromo-4-chloro-3-indoyl-beta-D-galactopyranoside (X-GAL), 20 ul of 100 mM isopropyl-beta-thio-
10 galactopyranoside (IPTG) and 2.5 ml of molten top agar (0.7 g Bacto-Agar/100 ml in LB medium) that had been cooled to about 50C was admixed to the solution. The resulting solution was immediately poured onto the
15 surface of bacterial plates consisting of 15 g/L Bacto-Agar in LB medium. The agar was allowed to cool for about 10 minutes and then the plates were inverted and maintained overnight at 37C during which time plaques developed in the MV1190 cell lawn.

20 Isolated plaques resulting from the above transformation were picked and grown up according to standard procedures described in the instruction provided with the Muta-Gene Kit (Bio-Rad Laboratories, Richmond, CA). Double-stranded RF DNA was then
25 produced from each plaque using the alkaline lysis mini-prep procedure described in Molecular Cloning: A Laboratory Manual, Maniatis et al., eds., Cold Spring Harbor Laboratory, NY (1982). The resulting DNA was then digested with restriction endonucleases that
30 allow the identification of mutants containing the desired polynucleotide.

Mutants identified in this manner were then sequenced to confirm the DNA sequence of the mutant cDNA coding for either immunoglobulin heavy chain or
35 immunoglobulin light chain.

2. Construction Of Expression Vectors Containing Kappa Light Chain Genes

An expression vector containing the entire kappa light chain gene including the kappa leader was produced in the following manner. The full length kappa light gene cDNA isolated above was mutagenized using polynucleotides P1 and P3 (Table 2) and the mutagenesis procedures described above.

Polynucleotide P1 introduces an Eco RI restriction endonuclease site at the 5' end of the full length kappa cDNA. Polynucleotide P3 introduces an Eco RI restriction endonuclease site at the 3' end of the full length kappa light chain cDNA clone. Mutant transformants containing 2 additional Eco RI restriction endonuclease sites indicating that both polynucleotide P1 and polynucleotide P3 had been introduced into the mutants were isolated. These mutants were then sequenced to confirm that they did contain the DNA sequence of both polynucleotide P1 and polynucleotide P3.

The full length kappa light chain cDNA (Figure 1A) was excised with the restriction endonuclease Eco RI sites at the 5' and 3' ends and the restriction fragment isolated using gel electrophoresis. This isolated restriction fragment was directly ligated to the pMON530 expression vector that had been previously digested with Eco RI (Figure 2). The resulting ligation mixture was transformed into suitable host cells and individual transformants isolated. DNA was prepared from the individual transformants using procedures similar to the standard of procedures described in Molecular Cloning: A Laboratory Manual, Maniatis et al., Cold Spring Harbor Laboratory, NY (1982). The transformant DNA was then digested with various restriction end nucleases to establish th

orientation of the kappa light chain cDNA gen within
th xpression v ctor. The resulting kappa light
chain expression vector contained a gene coding for
the entire kappa chain including the kappa leader.

5 An expression vector containing the kappa
light chain gene without its leader sequence was
produced in the following manner. The full length
kappa light chain genes cDNA isolated above was
mutagenized using polynucleotides P2 and P3 (Table 2)
10 and the mutagenesis described above. Polynucleotide
P2 introduces an Eco RI restriction endonuclease site
just 5' of the sequence that codes for the N-terminal
amino acid of the mature kappa light chain and thus
removes the kappa light chain leader sequence normally
15 transcribed in the wild type cDNA. Polynucleotide P3
introduces an Eco RI restriction endonuclease site at
the 3' end of the full length kappa light chain cDNA
clone. Mutant transformants containing 2 additional
Eco RI restriction endonuclease sites indicating that
20 both polynucleotide P2 and polynucleotide P3 had been
introduced into the mutants were isolated. These
mutants were then sequenced to confirm that they did,
in fact, contain the DNA sequence of both
polynucleotide P2 and polynucleotide P3.

25 The leaderless kappa light chain cDNA produced
by this mutagenesis was excised with the restriction
endonuclease Eco RI sites at the 5' and 3' ends and
the restriction fragment isolated using gel
electrophoresis. This isolated restriction fragment
30 was directly ligated to the pMON530 expression vector
that had been previously digested with Eco RI (Figure
2). The resulting ligation mixture was transformed
into suitable host cells and individual transformants
isolated. DNA was prepared from the individual
35 transformants and the transformant DNA was then

digested with various restriction endonucleases to establish the orientation of the leaderless kappa light chain cDNA gene within the expression vector. The resulting leaderless kappa light chain expression vector contained a gene coding for the kappa chain without its normal leader sequence.

Table 2

Mutagenic Polynucleotides

(P1)-5'-TGTGAAAACCATATTGAATTCCACCAATACAAA-3'
 (P2)-5'-ATTTAGCACAAACATCCATGTGCGACGAATTCAATCCAAAAAGCAT-3'
 (P3)-5'-GGGGAGCTGGTGGTGGGAATTCGTCGACCTTTGTCTCTAACAC-3'
 (P4)-5'-CCATCCCATGGTTGAATTCAGTGTGTCGTCAG-3'
 (P5)-5'-CTGCAACTGGACCTGCATGTGCGACGAATTCAGCTCCTGACAGGAG-3'
 (P6)-5'-CCTGTAGGACCAGAGGAATTCGTCGACACTGGGATTATTTAC-3'

3. Construction Of Expression Vectors
Containing Gamma Heavy Chain Gene

An expression vector containing the entire gamma heavy chain gene including the gamma leader was produced in the following manner. The full length gamma heavy chain gene cDNA isolated above was mutagenized using polynucleotides P4 and P6 (Table 2) and the mutagenesis procedures described above. Polynucleotide P4 introduces an Eco RI restriction endonuclease site at the 5' end of the native full length gamma cDNA. Polynucleotide P6 introduces an Eco RI restriction endonuclease site at the 3' end of the full length gamma heavy chain cDNA clone. Mutant transformants containing 2 additional Eco RI restriction endonuclease sites indicating that both polynucleotide P4 and polynucleotide P6 had been

introduced into the mutants were isolated. These mutants were then sequenced to confirm that they did in fact contain the DNA sequence of both polynucleotide P4 and polynucleotide P6.

5 The full length gamma heavy chain cDNA was excised with the restriction endonuclease Eco RI at the 5' and 3' ends (Figure 1B) and the restriction fragment isolated using gel electrophoresis. This isolated restriction fragment was directly ligated to
10 the pMON530 expression vector that had been previously digested with Eco RI (Figure 2). The resulting ligation mixture was transformed into suitable host cells and individual transformants isolated. DNA was prepared from the individual transformants and the
15 transformant DNA was then digested with various restriction endonucleases to establish the orientation of the gamma heavy chain cDNA within the expression vector. The resulting gamma heavy chain expression vector contained a gene coding for the entire gamma
20 heavy chain including the gamma leader.

 An expression vector containing the gamma heavy chain gene without its leader sequence was produced in the following manner. The full length gamma heavy chain gene cDNA isolated above was
25 mutagenized using polynucleotides P5 and P6 (Table 2) and the mutagenesis procedures described above. Polynucleotide P5 introduces an Eco RI restriction endonuclease site immediately 5' of the sequences that code for the N-terminal amino acid of the mature
30 protein and thus remove the normal gamma leader sequence. Polynucleotide P6 introduces an Eco RI restriction endonuclease site at the 3' end of the full length gamma heavy chain cDNA clone. Mutant transformants containing 2 additional Eco RI
35 restriction endonuclease sites indicating that both

polynucleotide P5 and polynucleotide P6 had been introduced into the mutants were isolated. These mutants were then sequenced to confirm that they did contain both polynucleotide P5 and polynucleotide P6.

5 This leaderless gamma heavy chain cDNA was excised with the restriction endonuclease Eco R1 sites located at the 5' and 3' ends and the resulting restriction fragment isolated using gel electrophoresis. This isolated restriction fragment was directly ligated to the pMON530 expression vector that had been previously digested with Eco R1 (Figure 2). The resulting ligation mixture was transformed into suitable host cells and individual transformants isolated. DNA was prepared from the individual transformants and the transformant DNA was then digested with various restriction endonucleases to establish the orientation of the gamma heavy chain cDNA within the expression vector. The resulting gamma heavy chain expression vector contained a gene coding for the gamma heavy chain without its native gamma leader.

4. Introduction Of Immunoglobulin Genes Into Plants

25 The leaderless kappa expression vector, the leaderless gamma expression vector, the native kappa expression vector and the native gamma expression vector prepared in the above examples were mobilized into Agrobacterium strain GV3111-SE using the triparental conjugation system of Ditta et al., Proc. Natl. Acad. Sci. USA, 77:7347-7351 (1980). Briefly, the Agrobacterium (acceptor) GV3111-SE, was grown on an agar plate containing MGL medium consisting of 2.6 g/L yeast extract, 5 g/L tryptone, 5 g/L NaCl, 5 g/L mannitol, 1.16 g/L monosodium glutamate, 0.25 g/L

KH₂PO₄, 0.1 g/L MgSO₄-7H₂O per liter, and 1 mg/L biotin at pH 7.0 for 12 to 18 hr at 28C. The E. coli (helper) strain containing the mobilization plasmid pRK2073 described by Better et al., J. Bacteriol, 155:311 (1983), was grown on an agar plate containing LB agar (LB agar is 5 g/L yeast extract, 10 g/L tryptone, 10 g/L NaCl, 15 g/L Bacto-agar, at pH 7.0) for 12 to 18 hr at 37C. The E. coli containing each of the expression vectors were grown on bacterial culture plates containing LB medium supplemented with 3 ug/ml tetracycline and 10 ug/ml kanamycin for 12 to 18 hr at 37C. An equal amount (about 1 x 10⁸ cells) of all three bacteria, the acceptor Agrobacterium, the helper E. coli, and the E. coli containing the expression vectors were mixed together and plated out on a bacterial plate containing AB agar medium containing 100 ug/ml kanamycin, 200 ug/ml spectinomycin and 50 ug/ml chloramphenicol (1 liter AB medium agar contains 1 g NH₄Cl, 0.3 g MgSO₄-7H₂O, 0.15 g KCl, 0.01 g CaCl₂, 2.5 mg FeS₄-7H₂O, 3 g K₂HPO₄, 1.15 g NaH₂PO₄-H₂O, 5 g glucose and 15 g Bacto-agar). The bacterial culture plates were incubated at 28C for two to four days. Single transformant colonies were admixed into a culture flask containing LB medium supplemented with 100 ug/ml kanamycin, 200 ug/ml spectinomycin and 50 ug/ml chloramphenicol was maintained with gentle shaking at 28C for 12 to 18 hours. Each of the expression vectors prepared in the above examples were now in a culture of Agrobacterium and thus ready to be introduced into a plant.

Tobacco leaf discs were transformed using the methods described in Rogers et al., in Methods For Plant Molecular Biology, Academic Press, Inc., San Diego, CA (1988). Healthy, young tobacco leaves were surface sterilized by placing the leaves in a solution

containing 20% household bleach (w/v) and 0.1% SDS (w/v) for 8 minutes. The leaves were then transferred to a solution containing 98% ethanol for 60 seconds and rinsed twice in sterile double distilled H₂O. The

5 leaf discs were then punched with a 6-mm paper punch. The discs were placed basal side down, in MS10 solution (MS salts, Gibco Laboratories, Grand Island NY, 0.01 mg/ml thiamine HCL, 0.001 mg/ml pyridoxine HCL, 0.001 mg/ml nicotinic acid, and 0.1 mg/ml

10 inositol, 30 g sucrose, 0.01 ug/ml naphthalene acidic acid [NAA], 1.0 ug/ml benzyladenine [BA], and 10 g/l Bacto-agar at pH 6.0). Each disc was admixed to the culture of Agrobacterium containing the expression

15 vectors for 5 seconds. The discs were then blotted dry on sterile filter paper and transferred basal side down to the MS10 medium and the medium maintained for 48 hours under normal growing conditions. Each leaf disc was then washed in sterile water to remove most of the Agrobacterium containing the expression vector.

20 The leaf discs were blotted dry on sterile number 9 Whatman filter paper and then placed basal side up on MS10 medium selection plates containing 200 ug/ml kanamycin sulfate and 500 ug/ml carbenicillin. Selection plates were maintained under normal growing

25 conditions for two weeks. Within the two weeks, callus appeared and shortly later shoots appeared. After the shoots appeared, they were transferred to regeneration plates containing MS0 medium (MS10 with no NHA or BA) and 200 ug/ml kanamycin sulfate and 500

30 ug/ml carbenicillin. The shoots that rooted in the regeneration plates were transferred to soil to produce plantlets. The plantlets were maintained under standard growth conditions until they reached maturity.

A population of plantlets was prepared from each of the expression vectors constructed in the above examples using the procedure just outlined. Leaf extracts from each of the plantlet populations were screened for the presence of immunoglobulin heavy or light chain using an ELISA assay based on the methods described by Engvall et al., J. Immunol., 109:129-135 (1972). Briefly, 50 ul of a solution containing 150 mM NaCl and 20 mM Tris-Cl at pH 8.0 (TBS), and either a goat anti-mouse heavy chain or a goat anti-mouse light chain specific IgG (Fisher Scientific, Pittsburgh, PA) was admixed into the wells of microtiter plates. The plates were maintained for about 16 hours at 4C to permit the goat antibodies to adhere to the microtiter well walls. After washing the wells four times with H₂O, 200 ul of TBS containing 5% non-fat dry milk admixed to the microtiter wells. The wells were maintained for at least 30 minutes at 20C, the wells emptied by shaking and blotted dry to form a solid support, i.e., a solid matrix to which the goat antibodies were operatively attached.

Leaves from each of the transformants were homogenized in a mortar and pestle after removing the midvein. One-fourth volume of 5x TBS (750 mM NaCl and 100 mM Tris-Cl at pH 8.0) was admixed to the homogenized transformant leaves. Two-fold serial dilutions of the homogenate were made in TBS (150 mM NaCl and 20 mM Tris-Cl at pH 8.0). 50 ul of the two-fold serial dilutions were added to each separate microtiter well and the wells maintained for 18 hours at 4C to permit the formation of solid-phase immunoreaction products. The wells were then washed with room temperature distilled water. 50 ul of a 1:1000 dilution of either goat anti-mouse heavy chain

or goat anti-mouse light chain specific antibody conjugated to horse radish peroxidase (HRPO) (Fisher Scientific, Pittsburgh, PA) in TBS was admixed to each of the microtiter wells. The wells were maintained for 2 hours at 37C followed by detection according to the manufacturer's instructions. Control microtiter wells were produced in a similar fashion and contained extracts from plants transformed with the vector alone and did not express any detectable immunoglobulin products.

The immunoglobulin content of each plantlet was determined at least twice and the values shown in Table 3 are given as mean values. At least 9 plantlets from each population of plantlets were assayed in this manner. The plantlets expressing either immunoglobulin heavy chain or immunoglobulin light chain were now shown to be transformed with the immunoglobulin genes and are thus termed transformants or transgenic plants.

Table 3

Expression of Immunoglobulin Gamma and
Kappa Chains in Tobacco

	Gamma-NL	Gamma-L
25	30±16	1412±270
	(60)	(2400)
30	Kappa-NL	Kappa-L
	1.4±1.2	56±5
35	(3.5)	(80)

The results present in Table 3 demonstrate the importance of a signal sequence for the accumulation of the individual immunoglobulin chains. Kappa chain accumulation was 40-fold greater (on average) when the signal sequence was present in the cDNA construct; Gamma chain accumulation was 47-fold greater.

5. Producing a Population of Progeny
Expressing Both Immunoglobulin Heavy and
Immunoglobulin Light Chain

Transformants produced according to Example 4 expressing individual immunoglobulin chains were sexually crossed to produce progeny expressing both chains. Briefly, the hybrid progeny were produced by was to emasculating immature flowers by removing the anthers from one transformant expressing one immunoglobulin chain to produce a female transformant. The female transformant is then cross-pollinated from the other transformant (male) expressing the other immunoglobulin chain. After cross-pollination, the female transformant was maintained under normal growing conditions until hybrid seeds were produced. The hybrid seeds were then germinated and grown to produce hybrid progeny containing both the immunoglobulin heavy chain and the immunoglobulin light chain. A schematic diagram of producing hybrid progeny is shown in Figure 3. The leaves were homogenized and the homogenate assayed for immunoglobulin heavy chain or light chain expression using the ELISA assay described in Example 4. The number of hybrid progeny expressing immunoglobulin heavy chain or immunoglobulin light chains is shown in Table 4. The hybrid progeny produced from the cross of th transformants expr ssing the Kappa leader

construct and the gamma leader construct contained assembled immunoglobulin molecules containing both gamma heavy chains and kappa light chains.

5

Table 4

Expression of Immunoglobulin Gamma and
Kappa Chains in Hybrid Progeny

	Gamma-L	Gamma-NL
	(Kappa-L)	(Kappa-NL)
10	3330±2000	32±26
	(12800)	(60)
	Kappa-L	Kappa-NL
	(Gamma-L)	(Gamma-NL)
15	3700±2300	6.5±5
	(12800)	(20)

Table 5

Expression and Assembly of Immunoglobulin
Gamma and Kappa Chains in Hybrid Progeny

	Gamma <u>only</u>	Kappa <u>only</u>	Gamma <u>Kappa</u>	<u>null</u>
25				
	Kappa-NL X	4	6	3
	Gamma-NL			5
	assembly)			(0%
30	Kappa-L X	3	10	11
	Gamma-L			4
				(95±16% assembly)

The results presented in Tables 4 & 5 demonstrate the importance of assembly of the two immunoglobulin chains.
35 Compared to the parental transformants, the progeny that

expr ss both immunoglobulin chains together accumulat for
more of each chain. On averag , gamma chain show d a 2.5-
fold increase in accumulation and kappa chain a 66-fold
increase.

5 Compared to the transformants expressing cDNAs
without leader sequences, the increased accumulation as a
result of both the leader sequence and dual expression
resulting from the sexual cross was surprisingly large.
Gamma chains increased by 110-fold and kappa chains by
10 2,600-fold.

6. Detection of Immunoglobulin Heavy
Chain-coding Genes and Immunoglobulin Light
Chain-Coding Genes in the Transgenic Plants

15 The presence of immunoglobulin heavy chain-coding
genes or immunoglobulin light chain-coding chains in th
transgenic plants and hybrid progeny was demonstrated by
analyzing DNA extracted from the transgenic plants using
the Southern blot procedure described in Maniatis et al.,
20 Molecular Cloning: A Laboratory Manual, Cold Spring Harbor
Laboratory, NY (1982). Briefly, DNA was extracted from 1
g of mature leaf tissue harvested from either the heavy
chain gene transformants, the light chain gene
transformants or the hybrid progeny after freezing the
25 leaf segments in liquid nitrogen. The frozen leaf
segments were homogenized in urea mix (420 g/L urea, 3.2.5
mM NaCl 50 mM Tris-Cl at pH 8.0, 20 mM EDTA and 1%
sarcosine) with a mortar and pestle according to the
procedures described by Shure, et al., Cell, 25:225-233
30 (1986). The leaf homogenate was extracted with
phenol:CHCl₃ (1:1 v/v) and the nucleic acids were
precipitated by adding 1/6 volume of 4.4 M ammonium
acetate at pH 5.2 and one volume of isopropyl alcohol and
then maintaining the resulting solution at -20C for 30
35 minutes. The solution containing the precipitated nucleic

acid was centrifuged for 15 minutes at 7500 x g at 4C to collect the precipitated nucleic acid. The nucleic acid pellet was resuspended in a TE solution containing 10 mM Tris-Cl at pH 7.6 and 1 mM EDTA. The concentration of DNA in the resulting solution was determined by spectrophotometry.

DNA was prepared from each of the transformants using the above methods and 20 ug of transformant DNA was digested with the restriction endonuclease Hind III under conditions recommended by the manufacturer, Stratagene Cloning Systems, La Jolla, CA. The resulting restriction endonuclease fragments were size fractionated on an agarose gel and blotted to nitrocellulose using the methods described in Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, NY (1982). Briefly, after the DNA had been size fractionated by electrophoresis through an agarose gel, the DNA was stained ethidium bromide and a photograph of the gel produced. The gel containing the DNA was placed in a solution containing 1.5 M NaCl and 0.5 M NaOH for one hour at room temperature with constant gentle stirring. The gel was then placed in a solution containing 1 M Tris-Cl at pH 8.0 and 1.5 M NaCl for one hour at room temperature with constant gentle stirring. The pH of the gel was periodically checked by removing a small piece of the gel and determining its pH in a small volume of distilled H₂O. When the gel had reached a pH of approximately 8.0 the gel was placed upon a thick wick soaked with a solution containing 87.65 g/L NaCl, 13.8 g/L NaH₂PO₄-H₂O and 3.7 g/L EDTA at pH 7.4 (10X SSC). A piece of nitrocellulose filter (Schleicher and Schuell BA 85, Keene, NH) that had been previously cut to the same size as the gel and soaked in a solution containing 10X SSC was placed upon the gel and any intervening air bubbles removed. Two pieces of Whatman 3 MM paper, cut to exactly the same size as the

nitrocellulose filter were soaked in 2X SSC (2X SSC contains 17.53 g/L NaCl, 2.76 g/L $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ and 0.74 g/L EDTA at pH 7.4) and placed on top of the nitrocellulose filter and any intervening air bubbles removed. A stack of paper towels (5-8 centimeters high) cut to a size just slightly smaller than the Whatman 3 MM paper was placed on top of the Whatman 3 MM paper. A glass plate was placed on top of the resulting stack and a 500 gram weight placed on top of the plate. The resulting capillary action was allowed to proceed for 12 to 24 hours and this action transferred the DNA from the gel onto the nitrocellulose filter. The stack was disassembled and the nitrocellulose filter soaked in 6X SSC (6X SSC is 52.59 g/L NaCl, 8.28 g/L $\text{NaH}_2\text{PO}_4 \cdot \text{H}_2\text{O}$ and 2.22 g/L EDTA at pH 7.4) at room temperature for five minutes. The filter was placed upon a piece of dry Whatman 3 MM paper and allowed to air dry. The dried filter was placed between two sheets of 3 MM paper and baked for 2 hours at 80°C under vacuum to operatively link the DNA to the nitrocellulose filter.

The baked filters were placed on the surface of a solution containing 0.9 M NaCl and 0.09 M sodium citrate at pH 7.0 until they were thoroughly wetted from beneath. The filters were submerged in the same solution for 5 minutes.

The filters were placed in a pre-hybridization solution containing 50% formamide, 0.9 M NaCl, 0.05 M NaPO_4 at pH 7.7, 0.005 M EDTA, 0.1% ficoll, 0.1% BSA, 0.1% poly(vinyl pyrrolidone), 0.1% SDS and 100 ug/ml denatured, salmon sperm DNA. The filters were maintained in the pre-hybridization solution for 12 to 18 hours at 42°C with gentle mixing. The filters were then removed from the pre-hybridization solution and placed in a hybridization solution consisting of pre-hybridization solution containing 1×10^6 cpm/ml of ^{32}P -labeled gamma chain probe (the entire gamma expression vector was labeled) and $1 \times$

10⁶ cpm/ml of ³²P-labeled kappa chain probe (the entire
expression kappa vector was labeled. The filters were
maintained in the hybridization solution for 12 to 24
hours at 42C with gentle mixing. After the hybridization
5 was complete the hybridization solution was discarded and
the filters washed 4 times for 10 minutes per wash in a
large volume of a solution containing 0.3 M NaCl, 0.03 M
sodium citrate at pH 7.0 and 0.1% SDS at room temperature.
The filters were then washed twice for 1.5 hours in a
10 solution containing 0.15 M NaCl, 0.015 M sodium citrate at
pH 7.0, and 0.1% SDS at 65C. The filters were further
washed by transferring them to a solution containing 0.2x
SSC (0.03 M NaCl and 0.003 M sodium citrate at pH 7.0) and
0.1% SDS at 42C for 1 hour with gentle agitation. The
15 filters were removed from the washing solution and air
dried on a sheet of Whatman 3 MM paper at room
temperature. The filters were then taped to sheets of 3
MM paper and wrapped with plastic wrap and used to expose
X-ray film (Kodak XR or equivalent) at -70C with an
20 intensifying screen to produce an autoradiogram. The film
was developed according to manufacturers' directions.

The resulting autoradiogram is shown in Figure 4A.
The hybridizing DNA fragments detected in the
transformants expressing either the kappa light chain cDNA
25 without a leader sequence (Lane 1) or with its native
leader sequence (Lane 3) are shown. The hybridizing DNA
fragment detected in DNA from transformants expressing
either the gamma heavy chain cDNA without a leader
sequence (Lane 2) or with its native leader sequence (Lane
30 4) are shown. The hybridizing DNA fragments detected in
hybrid progeny containing both kappa light chain with its
native leader and gamma heavy chain with its leader (Lane
5) are shown.

7. Detection Of mRNA Coding For Immunoglobulin Heavy And Light Chains In The Transgenic Plants

The presence of mRNA coding for immunoglobulin heavy chain or immunoglobulin light chain gene in the transgenic plants and hybrid progeny was demonstrated by analyzing RNA extracted from the transgenic plants using procedures similar to those described by Molecular Cloning, A Laboratory Manual, supra. Briefly, RNA was extracted from 1 g of mature leaf tissue harvested from either the heavy chain gene transformants, the light chain gene transformants or the hybrid progeny. The leaf tissue was cut into small pieces and admixed to 10 ml of a solution containing 10 ml of 0.1 M Tris-Cl at pH 9.0 and phenol saturated with this buffer. The leaf tissue was immediately homogenized in the solution using a Polytron homogenizer at high speed for 1 minute. The homogenate was centrifuged at 4,000 x g for 15 minutes at room temperature. The resulting aqueous phase was recovered and the RNA precipitated by admixing 1 ml of 3 M sodium acetate at pH 5.2 and 25 ml of isopropanol. This solution was maintained at -20C for 20 minutes to precipitate the RNA present. The precipitated RNA was collected by centrifuging this solution at 4,000 x g for 15 minutes at 4C. The resulting RNA pellet was resuspended in 400 ul of DEPC-H₂O and transferred to a 1.5 ml Eppendorf tube. This solution was centrifuged in an Eppendorf microfuge for 5 minutes at top speed. The resulting supernatant was transferred to a new eppendorf tube and 40 ul of 3 M sodium acetate at pH 5.2 and 1 ml of absolute ethanol admixed to it. This solution was maintained at -20C for 20 minutes and then centrifuged for 5 minutes in an eppendorf microfuge. The resulting RNA pellet was resuspended in 400 ul of depc-H₂O and a small aliquot removed to determine the RNA conc ntration by absorbance

at 260 nm. The remainder of the solution was frozen at -70C until used.

5 The RNA prepared above was size fractionated on denaturing formaldehyde agarose gels and transferred to nylon membrane. The procedures used were similar to the procedures described in Molecular Cloning: A Laboratory Manual, Maniatis et al., eds., Cold Spring Harbor Laboratories, NY (1982). Briefly, the denaturing formaldehyde agarose gel was prepared by melting 1.4 g of
10 agarose in 73.3 ml of DEPC-H₂O water and cooling this solution to 60C in a water bath. 10 ml of a buffer containing 50 mM NaH₂PO₄, 50 mM Na₂HPO₄, 50 mM sodium acetate and 10 mM EDTA was admixed to this solution. 16.66 ml of 37% formaldehyde was also admixed to the
15 solution and the solution poured into a gel mold and allowed to solidify. The denaturing formaldehyde agarose gel was now ready for use.

A 20 ug aliquot of RNA prepared above was admixed to 15 ul of formamide, 5 ul of 37% formaldehyde and 3 ul
20 of a buffer containing 50 mM NaH₂PO₄, 50 mM Na₂HPO₄, 50 mM sodium acetate and 10 mM EDTA. This solution was maintained at 55C for 15 minutes and then immediately placed on ice. One/tenth volume of a solution containing 50% glycerol 1 mM EDTA 0.4% bromophenol blue and 0.4%
25 xylene cyanol was thoroughly admixed to this solution and the solution loaded onto the denaturing formaldehyde gel prepared above. The gel was electrophoresed in a buffer containing 5 mM NaH₂PO₄, 5 mM Na₂HPO₄, 5 mM sodium acetate and 1 mM EDTA for 2 hours at room temperature. After the
30 electrophoresis was complete the gel was soaked in several changes of water for 10 to 15 minutes. The gel was then placed in a solution containing 0.1 M Tris-Cl at pH 7.5 for 45 minutes. The gel was then placed in a solution containing 3 M NaCl and 0.3 M sodium citrate at pH 7.0.
35 Th gel was then placed on a thick wick soaked with a

solution containing 1.5 M NaCl and 0.15 M sodium citrate at pH 7.0. A sheet of nylon membrane (Hybond-N, Amersham Corporation, Arlington Heights, IL) that had been previously cut to the same size as the gel and soaked in a solution containing 10x SSC was placed on the gel and any intervening air bubbles removed. Two pieces of Whatman MM paper, cut to exactly the same size as the nylon membrane were soaked in 2x SSC (0.3 M NaCl and .03 M sodium citrate at pH 7.0) and placed on top of the nylon membrane and any intervening air bubbles removed. A stack of paper towels (5-8 cm high) cut to a size just slightly larger than the Whatman 3 MM paper was placed on the top of the Whatman 3 MM paper. A glass plate was placed on top of the resulting stack in a 500 g weight placed on top of the plate. The resulting capillary action was allowed to proceed for 12 to 24 hours and this action transferred the RNA from the gel to the nylon membrane. The stack was disassembled and the nylon membrane soaked in 6x SSC (0.9 M NaCl and 0.09 M sodium citrate at pH 7.0) at room temperature for 5 minutes. The nylon membrane was then placed on a ultraviolet radiation box for 10 minutes to operatively link the RNA to the nylon membrane.

RNA containing either kappa light chain coding sequences or gamma heavy chain coding sequences was detected by prehybridizing and hybridizing the nylon membrane using the protocol described in Example 6. The resulting autoradiogram is shown in Figure 4B. The hybridizing RNA species detected in RNA from transformants expression either the kappa light chain cDNA without a leader sequence (Lane 1) or with its native leader sequence (Lane 3) are shown. The hybridizing RNA species detected in RNA from transformants expressing either the gamma heavy chain cDNA without a leader sequence (Lane 2) or its native leader sequence (Lane 4) are shown. The hybridizing RNA species detected in hybrid progeny

containing both kappa light chain with its native leader and gamma heavy chain with its native leader (Lan 5) as shown.

5 8. Detection of Immunoglobulin Heavy And Light Chains In The Transgenic Plants

 The expression of immunoglobulin heavy and light chains in the transgenic plants and hybrid progeny was demonstrated by Western blotting in which both heavy and light chains were detected. Using the Western blot procedure described in Antibodies: A Laboratory Manual, Harlow & Lane, eds., Cold Spring Harbor Laboratories, NY (1988). Briefly, 1g of leaf segments mature plants were homogenized in a mortar and pestle with 1 ml of 0.05 M Tris-Cl at pH 7.5, and 1 mM phenylmethylsulfonyl fluoride (PMSF) 1/10 of the resulting leaf extract was admixed to a solution with a final concentration of 4 M urea and 1% SDS with or without 2 mM DTT as indicated and the solution boiled for 3 minutes. After boiling this solution was electrophoresed through a 10% polyacrylamide gel containing SDS (SDS-PAGE) as described in NH. Chua, Methods in Enzymol, 69:434-446 (1980). The electrophoresed proteins were then transferred (affixed) to a sheet of nitrocellulose as described in Antibodies: A Laboratory Manual, Harlow and Lane, eds., Cold Spring Harbor Laboratory, NY (1988). Briefly, the nitrocellulose sheet was placed in a solution containing 20 mM Tris-Cl at pH 8.0, 150 mM NaCl and 0.01% polyoxyethylene sorbitan monolaurate (Tween 20) (TBST) containing 5% bovine serum albumin (BSA) and 0.5% non-fat dried milk. The nitrocellulose sheet was maintained in this solution for 6 hours at 4C. The nitrocellulose was then placed in a solution containing a 1:500 dilution of a biotinylated goat anti-mouse whole IgG antibody (Cappel, Malvern, PA) in TBST and the solution containing the nitrocellulose

sheet maintained at 4C for 24 hours. During this time, the immunoglobulin heavy chains and the immunoglobulin light chains immobilized on the nitrocellulose sheet immunoreacted with the biotinylated goat anti-mouse whole IgG antibody to form an immunoreaction product on the nitrocellulose sheet. The nitrocellulose sheet was removed from this solution and washed with TBST solution and then placed in a TBST solution containing streptavidin-conjugated alkaline phosphatase (Fisher Scientific, Pittsburgh, PA). This solution was maintained for 1 hour at 25C. The nitrocellulose sheet was removed from this solution and washed with TBST.

The immunoreaction product was visualized by maintaining the nitrocellulose sheet in a solution containing 100 mM Tris-Cl at pH 9.5, 100 mM NaCl, 5 mM $MgCl_2$, 0.3 mg/ml of nitro blue tetrazolium (NBT) and 150 ug/ml 5-bromyl-4-chloryl-3-indolyl phosphate (BCIP) for 30 minutes at room temperature. The residual color development solution was rinsed from the filter with a solution containing 20 mM Tris-Cl at pH 7.5 and 150 mM NaCl. The filter was then placed in a stop solution consisting 1 mM EDTA, pH8. The development of an intense purple color indicated the location of the immunoreaction products.

Expression of immunoglobulin heavy chain in the heavy chain transformants, immunoglobulin light chain in the light chain transformants and both immunoglobulin heavy and light chains in the hybrid progeny was demonstrated using the Western blot (Figure 5). In addition, the immunoglobulin heavy and light chains produced in the hybrid progeny were assembled into immunoglobulin molecules as evidenced by the high molecular weight immunoreactive gamma and kappa chain seen under non-reducing conditions (Figure 5).

9. Immunoglobulin Molecules Expressed In The Transgenic Plants Bind Antigen

The binding of antigen by the immunoglobulin molecules expressed in the transgenic plants was demonstrated using an ELISA assay similar to the ELISA assay described in Example 4. This antigen binding ELISA assay was modified in the following manner. Instead of adhering the goat antibodies to the microtitre well walls, the antigen P3 conjugated to BSA according to the methods described in Tramontano et al., Proc. Natl. Acad. Sci. USA, 83:6736-6740 (1986), was adhered to the microtitre well walls. Leaf homogenate from each of the plantlet populations were then added to the wells and the binding of the immunoglobulin molecules present in the homogenate detected using goat anti-mouse heavy chain conjugated to HRP as described in Example 4.

The immunoglobulin molecules expressed in the transgenic plant directly bound their specific antigen, P3 in this antigen binding ELISA assay. To demonstrate the specificity of this antibody antigen interaction, an additional competitive ELISA assay was performed. This assay was similar to the antigen binding ELISA assay described above except that before the serial dilutions of leaf homogenate, 5 ul of a 500 uM solution of P3 was added to a duplicate well to act as a competitor for antibody binding to P3-BSA adhered to the microtitre well walls. The remainder of this competition ELISA assay was carried out according to Example 4.

The interaction between the antibodies expressed in the transgenic plants and their specific antigen, P3, was specifically inhibited by free antigen in this competition ELISA assay.

10. Catalytic Activity Immunoglobulin Expressed in Transgenic Plants

The catalytic activity of immunoglobulin molecules expressed in transgenic plants was demonstrated by purifying the 6D4 immunoglobulin molecule from tobacco plants expressing the functional immunoglobulin and assaying the purified immunoglobulin molecule to measure catalytic activity.

Briefly, plants containing assembled immunoglobulin molecules were produced using the method and procedures described in Examples 1, 2, 3, 4, 5, 6 and 8. The 6D4 immunoglobulin molecule was selected for expression in plants because a normally glycosylated 6D4 antibody produced in mice catalyzes the hydrolysis of carboxylic esters. See Tramontano et al., Science, 234:1566 (1986).

The 6D4 immunoglobulin was purified from the leaves of a tobacco plant expressing the immunoglobulin by sephacryl fractionation and absorption to Protein A-Sepharose. Briefly, midveins were removed from 10 grams (g) of young leaves which were then homogenized by hand in 50 ml of a homogenation buffer containing 50 mM of Tris-HCl at pH 8.0 and 1 mM PMSF. The resulting homogenate was centrifuged at 10,000 xg and the resulting supernatant concentrated to a final volume of 10 ml using a Centricon 30 (Amicon, Danvers, MA). The concentrated homogenate was then loaded onto a previously prepared sephacryl S-300 column. The column was eluted with 0.1 M sodium acetate at pH 5.0 and 1 ml fractions of eluate collected. The amount of immunoglobulin present in each of the collected fractions was determined using the ELISA assay described in Example 4.

The fractions containing the majority of the eluted immunoglobulin were pooled and extensively dialyzed against a binding buffer containing 1.5 M glycine at pH 8.9 and 3.0 M NaCl. After dialysis, the immunoglobulin was slowly passed twice over a column containing 2 g of

protein A-sepharose (Pharmacia, Piscataway, NJ) to allow the immunoglobulin to bind to the column. The protein A-sepharose was washed with 20 ml of binding buffer. The bound immunoglobulin was eluted with 10 ml of elution
5 buffer containing 0.1 M citrate at pH 6.0. The eluate was concentrated to 50 ug of immunoglobulin per ml using a Centricon 30. The concentrated immunoglobulin was then dialyzed against a 50 mM phosphate buffer at pH 8.0. The final concentration of immunoglobulin present in the
10 resulting solution was determined using an Elisa assay described in Example 8.

The amino acid sequence of the resulting 6D4 immunoglobulin was determined using the methods described
15 by Matsudaira, P., J. Biol. Chem., 262:10035-10038 (1987). Briefly, the gamma heavy chain and kappa light chain of the 6D4 immunoglobulin were separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) by loading approximately 1 ug of 6D4 immunoglobulin onto a 10% polyacrylamide gel. The immunoglobulin was
20 electrophoresed until the gamma heavy chain and Kappa light chain were separated. The separated gamma heavy chain and kappa light chain were then blotted onto a polyvinylidene difluoride membranes as described by Matsudaira, P., J. Biol. Chem., 262:10035-10038 (1987) and
25 the amino acid sequence determined.

Mouse derived 6D4 monoclonal antibody was purified from mouse ascites using the same procedure as that used to purify the antibody from plant leaves. Briefly, the mouse derived ascites fluid containing the 6D4 monoclonal
30 antibody was fractionated on a Sephacryl (S-300) column and a protein A-sepharose column. The resulting purified mouse monoclonal 6D4 antibody was at a final concentration of 500 ug/ml in a 0.1M citrate, pH 6.0 buffer containing.

The plant derived and mouse derived 6D4 antibodies
35 were assayed for catalytic activity by incubating the

purified antibodies with a substrate (Figure 9) in the presence or absence of a specific inhibitor (Figure 9) as previously described by Tramontano et al., Science 234:1566-1569 (1986). Briefly, approximately 100 nM of mouse derived 6D4 antibody or plant derived 6D4 antibody was preincubated at 25C in 50 mM phosphate buffer at pH 8.0. A series of reaction admixtures were formed by admixing varying amounts of dioxane stock solution containing substrate to produce a series of reaction admixtures containing 5% dioxane and a substrate concentration ranging from 1 to 8 mM. The reaction admixtures were maintained for 1 hour at 25C. and the hydrolysis of the ester substrate (Figure 9) measured on a Hewlett-Packard 8452A diode array spectrophotometer by monitoring the adsorption change at 245 nanometers (nm). The maximum adsorption change was measured by adding a non-specific esterase (Sigma, St. Louis, MO) to a control reaction admixture. The kinetic parameters were obtained after subtraction of background hydrolysis, using the Lineweaver-Burke data treatment described by Tramontano et al., Science, 234:1566 (1986). The inhibition constants were determined by plotting the slopes obtained with both 100 nM and 300 nM phosphonate (Table 6).

The catalytic activity of the purified plant derived and mouse derived 6D4 antibodies as measured by K_M , K_I , V_{max} and K_{cat} is shown in Table 6. The plant derived and mouse derived 6D4 antibodies differed by less than one order of magnitude.

Table 6Catalytic Activity of 6D4^b.

	<u>Source</u>	<u>Tobacco</u>	<u>Ascites</u>
	K_M	$1.41 \times 10^{-6} \text{ M}$	$9.8 \times 10^{-6} \text{ M}$
5	v_{\max}	$0.057 \times 10^{-8} \text{ M sec}^{-1}$	$0.31 \times 10^{-8} \text{ M sec}^{-1}$
	K_1	$0.47 \times 10^{-6} \text{ M}$	$1.06 \times 10^{-6} \text{ M}$
		(competitive)	(competitive)
	k_{cat}	0.008 sec^{-1}	0.025 sec^{-1}

^b This data was analyzed using a linear regression.

10

11. Production of Immunoglobulin with Heterologous Leader Sequences in Plants

To determine the effects of a heterologous leader
15 sequence on immunoglobulin assembly in plants, an
immunoglobulin cDNA containing the signal and pre-sequence
from the α -mating factor of Saccharomyces cerevisiae in
place of the native mouse leader sequences described in
Example 1 was prepared. The sequence of the α -mating
20 factor of Saccharomyces cerevisiae is shown in Table 7 and
has been described by Kurzan et al., Cell, 30:933-943
(1982).

Table 7

25 The sequence of the alpha-mating factor leader sequence
coupled to either gamma or kappa chain

GAATTCATTCAAGAATAGTTCAAACAAGAAGATTACAAACTATCAATTTCA
TACACAATATAAACGATTAAAAGA MRFPSIFTAVLFAASSAL
AAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVAVLP

30 FSNSTNNGLLFINTTIIASIAAKEEGVSLDLKR/DVVL
(kappa chain); /EVEL (gamma chain)

The underlined letters are the 5' untranslated nucleotides
of the yeast pre-pro sequence. The remaining letters are
the amino acids; / denotes the junction between the pr -
35 pro sequence and the kappa or gamma chains.

Briefly, the pre-pro sequence from the Saccharomyces cerevisiae α -mating factor described by Kurzan et al., Cell, 30:933-943 (1982) was subcloned into M13mp18 by first isolating the Eco R1 to Hind III restriction endonuclease fragment containing the α -mating factor from p69A. This α -mating factor containing restriction endonuclease fragment was then ligated to M13mp18 vector DNA that had been previously digested with Eco R1 and Hind III restriction endonucleases. The accuracy of this cloning step was determined by restriction endonuclease digestion of the resulting M13 clones containing the α -mating factor DNA.

The 6D4 kappa and gamma chain vectors without endogenous mouse leader sequences prepared in Example 1, were digested with Hind III and the resulting 5' phosphate groups removed. The α -mating factor vector was digested with Hind III restriction endonuclease to produce a Hind III restriction endonuclease fragment containing the α -mating factor. The α -mating factor containing restriction endonuclease fragment was isolated using an electroeluter (BRL, Bethesda, MD) after separation by agarose gel electrophoresis.

The isolated α -mating factor containing restriction endonuclease fragment was ligated to the Hind III digested gamma and kappa vectors in separate ligation reactions. Oligonucleotide-directed mutagenesis was used to remove the surplus nucleotides between the end of the α -mating factor pre-pro sequence and the Gln codon (gamma chain) or the Asp codon (kappa chain) to produce chimeric cDNAs. The accuracy of the oligonucleotide-directed mutagenesis was confirmed by DNA sequencing.

The chimeric cDNA's containing the α -mating factor pre-pro sequence and either the gamma or kappa immunoglobulin coding sequence were inserted into the PMON530 vector described by Rogers et al., Meth. Enzymol.,

153:253 (1987). Briefly, the chimeric cDNAs were attached to the pMON530 vector using the T4 DNA ligase. The products of the ligation reaction were introduced into E. coli using the bacterial strain and methods of Bethesda Research Laboratories (Bethesda, MD). Individual plasmids (recombinant pMON530 containing the chimeric cDNA) were analyzed by restriction endonuclease digestion and sequencing.

The resulting chimeric gamma and kappa cDNA expression vectors were used to transform leaf discs as described by Horsch et al., Science, 227:1229-1231 (1985) and in Example 4.

Individual plants expressing the gamma chain and individual regenerated plants expressing the kappa chain were selected. After confirming that the regenerates expressed either gamma or kappa chain using the ELISA described in Example 4, the individual regenerates were sexually crossed to produce a gamma X kappa progeny. These progeny were screened for antibody production using the ELISA assay described in Example 4.

The individual regenerates expressing either the gamma_{mat} chain or the kappa_{mat} chain were crossed with plants expressing the native 6D4 antibody containing the endogenous mouse leader peptide to produce progeny containing the native gamma chain and the kappa_{mat} or progeny containing the gamma_{mat} and the native kappa chain. These progeny were also screened using the ELISA assay described in Example 4.

The level of antibody expression in each of these progeny was determined using the ELISA assay described in Example 4 and the results are reported in Table 8.

Table 8

Accumulation of Gamma or Kappa Chains
and Antigen Binding f Gamma/Kappa Complexes.

5	<u>gamma mat^a</u>	<u>kappa mat</u>
	743±260	48±8
	(1030)	(72)
	<u>gamma mat (kappa mat)^c</u>	<u>kappa mat(gamma mat)</u>
10	2410±1230	2280±1300
	(7700)	(7700)
	<u>gamma mat(kappa mouse)</u>	<u>kappa mat(gamma mouse)</u>
	2615±1505	2490±1175
15	(8300)	(8300)
	<u>gamma mat(kappa no leader)</u>	<u>kappa mat(gamma no leader)</u>
	705±300	38±8
	(0)	(0)

20

* Values are expressed in ng/mg total protein (mean ±S.E.) where purified 6D4 antibody from mouse ascites was used as the ELISA standard. Numbers in parenthesis are highest levels of expression.

25

^c α(K) refers to the abundance of α chain in a plant which also expresses K chain and vice versa (i.e. progeny of sexual cross) as measured by ELISA. In these cases, values in parentheses are the result of antibody binding to ELISA plates coated with the phosphonate antigen (P3) (previously described by Tramontano et al., Proc. Natl. Acad. Sci., USA, 83: 6736-6740 (1986)) conjugated to BSA Hiatt et al., Nature, 342: 76-78 (1989). Only plants expressing the highest levels of K complex were used in the antigen binding assays.

30

35

The individual gamma and kappa chains containing the Saccharomyces cerevisiae leader sequence accumulated at nearly the same levels as constructs expressing the native mouse leader that were previously reported in Hiatt et al., Nature, 342:76-78 (1989). In addition, functional antibody was produced by crossing either gamma and kappa chains containing the same signal (gamma_{mat} X kappa_{mat}) or different signals (kappa_{mat} X gamma_{native}; kappa_{native} X gamma_{mat}). This is in contrast to crosses of plants in which one parent expressed a immunoglobulin without a leader did not result in production of functional antibody molecules as reported by Hiatt et al., Nature, 342: 76-78 (1989).

The fidelity of processing of the mouse immunoglobulin N-termini by the plant endomembrane system was determined by automated sequence analysis as described by P. Matsudaisa, J. Biol. Chem., 262:10035-10038 (1987). Mammalian kappa chains N terminal amino acid is typically aspartic acid as described by Kabat et al., Sequences of Proteins of Immunological Interest, Public Health Service, National Institutes of Health, Bethesda, Maryland. Many murine IgG1 gamma chains are blocked by pyroglutamic as reported by Johnston et al., Bioch. Biophys. Res. Commun., 66: 843-847 (1975). Sequence analysis suggested that the gamma chains derived from plants expressing the native mouse leader contained a blocked N-terminus. The end terminal sequence of kappa chains expressing the native mouse leader was Asp-Val-Val-Leu indicating the appropriate proteolytic processing of the kappa chain.

12. Glycosylation of Plant Derived Immunoglobulin Molecules

To determine the gamma chain glycosylation pattern of the plant derived immunoglobulin, the purified antibody was blotted onto nitrocellulose and probed with

biotinylated lectins as described by Faye et al., Anal. Biochem., 149:218-224 (1985). Briefly, the nitrocellulose membranes were incubated in a solution of 50 mM Tris-Cl, 0.5 M NaCl, 0.1 mM CaCl₂, 0.1 mM MgCl₂, and 0.1 mM MnCl₂ (TIBS) containing 1 ug/ml of a biotinylated lectin (Pierce, Rockford, IL) at room temperature for one hour. The filters were then washed with TIBS and incubated in TIBS containing 1 ug/ml streptavidin-alkaline phosphatase (Sigma, St. Louis, MO) for 1 hour at room temperature. The bound alkaline phosphatase was visualized using bromochloro-indolyl phosphate as described by Hiatt et al., Nature, 342:76-78 (1989).

In some cases, the purified antibody was incubated with 40 milliunits of endoglycosidase H (Signal Chemical Co., St. Louis, MO) in 50 ul of 200 mM sodium acetate at pH 5.8 for 2 hours at 37C prior to blotting to remove high mannose type sugars.

The results shown in Figure 10 indicate that only Concanavalin A, specific for mannose and glucose bound to the plant-derived antibody whereas the mouse ascites-derived antibody was recognized by Concanavalin A as well as the lectins from the Ricinus communis, specific for terminal galactose residues (N-acetylgalactosamine), and to a lesser extent by wheat germ agglutinin that is specific for N-acetylglucosamine dimers having terminal sialic acid residues. The specificity of the various lectins is discussed in Kijimoto-Ochiai et al., Biochem. J., 257:43-49 (1989). The lectins from Datura stramonium specific for N-acetylglycosamine oligomers and N-acetyl lactosamine and the lectin from Phaseolus vulgaris that is specific for Gal B1, 4 GlcNac B1, 2 mannose, did not bind to either the plant or mouse ascites derived gamma chain.

The elution of the lectins from the nitrocellulose blots using α -methylglucoside was used to compare the relative affinity of Concanavalin A binding to the plant-

derived and mouse ascites derived antibodies as has been previously described by Johnston et al., Bioch. Biophys. Res. Commun., 66:843-847 (1975). Using this assay, the plant-derived and mouse ascites-derived antibodies are indistinguishable with regards to Concanavalin A affinity as well as the quantity of Concanavalin A binding per microgram of gamma chain.

Digestion of either the plant-derived or mouse ascites-derived antibodies with endoglycosidase H using the conditions described by Trimvle et al., Anal. Biochem., 141:515-522 (1984) was carried out and the antibodies then transferred to nitrocellulose. The antibodies digested with endoglycosidase H displayed no reduction in Concanavalin A binding under conditions where Concanavalin A binding to ovalbumin was diminished.

Taken together these results indicate that the plant-derived immunoglobulin is processed through similar cellular compartments as the mouse ascites-derived antibody. The gamma chain Concanavalin A binding and resistance of the glycan to digestion by endoglycosidase H as well as the correct kappa chain N-terminus indicate that the antibody is migrating from the endoplasmic reticulum to the Golgi and is being secreted through the plasma membrane as described by Walter et al., Annu. Rev. Cell. Biol., 2:499-516 (1986).

The differential binding of several of the lectins to the plant-derived antibody indicates that the final glycosylation pattern of the plant-derived antibody and the mouse ascites-derived antibody are different. The plant-derived antibody did not bind to the lectins specific for terminal galactose and terminal sialic acid whereas the mouse ascites-derived antibody did.

13. Retention of Immunoglobulin Molecules Within the Plant Cell Wall

The rate of secretion of immunoglobulins from plants protoplast that did not contain cell walls was compared to the rate of secretion of immunoglobulin from plant cells having intact cell walls. The preparation of protoplasts from plant cells has been described by Tricoli et al., Plant Cell Report, 5:334-337 (1986). Briefly, 1 cm² pieces of tobacco leaf are incubated for 18 hours in a mixture of cellulysin (Calbiochem), macerase (Calbiochem) and driselase (Sigma) to digest cell walls and release protoplasts from the leaf. The protoplasts are purified by centrifugation (100 x g for 2 minutes) in 0.4 M Mannitol.

The immunoglobulin produced by either protoplast or intact plant cells was labeled by resuspending 2×10^6 protoplasts in 0.5 ml of a mannitol media containing and 10 uCi mCi of ³⁵S-methionine. The cells were maintained in this labeling medium for 2 hours and an aliquot of cells and medium was removed to determine the incorporated of labeled methionine into the 6D4 antibody. The amount of labeled 6D4 antibody in the incubation media was determined by adhering the immunoglobulin contained in the medium to a protein-A Sepharose column and determining the total radioactive counts adhering to the column. The amount of labeled methionine incorporated in the cells into the 6D4 antibody was determined by preparing the cells and loading the lysate onto a 10% SDS-PAGE gel and electrophoresing the lysate for 2 hours, as previously described by Hiatt et al., J. Biol. Chem., 261:1293-1298 (1986). The region of the SDS-PAGE gel containing the 6D4 antibody was cut out and the labeled antibody eluted from the gel. The total amount of labeled antibody present was then determined. In addition, the same measurements was made after a further maintenance of 2 hours in the presence of 100 mM methionine.

The callus cell lines were initiated over a period of 8 weeks by incubating leaf segments in the appropriate growth hormones as has been previously described by Hiatt et al., J. Biol. Chem., 261:1293-1298 (1986). The liquid suspensions cell lines were then initiated from clumps of the callus cells and used for the incorporation of ³⁵S-methionine as described above.

The results of this secretion analysis are shown in Table 9. After a 2 hour labeling period, a significant fraction of newly synthesized antibody was secreted from the protoplast. After a chase of 2 hours with 100 mM methionine, most of the total labeled antibody was secreted from the protoplast into the medium indicating that secretion of the antibody had occurred. In contrast, approximately 40% of the labeled antibody was retained within established callus suspension cell lines that had intact cell walls. These cells contain thin, primary cells walls and therefore retained the antibody within the cell wall.

Table 9

35 S-METHIONINE INCORPORATION
INTO 6D4 AT 2 HOURS (MEDIUM/CELLS)

PROTOPLASTS	PROTEIN A 0.33
"	SDS-PAGE 0.31
CALLUS SUSPENSION CELLS	PROTEIN A 0.39
"	SDS-PAGE 0.25

INCORPORATION INTO 6D4 AFTER 2 HOUR CHASE

PROTOPLASTS	PROTEIN A 6.60
"	SDS-PAGE 6.31
CALLUS SUSPENSION CELLS	PROTEIN A 2.77
"	SDS-PAGE 2.14

14. Production Of A Secretory IgA In A Plant CellA. Isolation of Messenger RNA Coding for
Pathogen Specific Variable Regions

A secretory IgA immunospecific for a preselected antigen is produced in plant cells by first isolating the variable region coding genes from a preselected hybridoma. Messenger RNA is prepared according to the methods described by Chomczynski et al., Anal. Biochem., 162:156-159 (1987) using the manufacturers instructions and the RNA isolation kit produced by Stratagene (La Jolla, CA). Briefly, approximately 1×10^7 cells are homogenized in 10 ml of a denaturing solution containing 4.0 M guanine isothiocyanate, 0.25 M sodium citrate at pH 7.0, and 0.1 M 2-mercaptoethanol using a glass homogenizer. One ml of sodium acetate at a concentration of 2 M at pH 4.0 is admixed with the homogenized cells. One ml of water-saturated phenol is admixed to the denaturing solution containing the homogenized cells. Two ml of a chloroform: isoamyl alcohol (24:1 v/v) mixture is added to the homogenate. The homogenate is mixed vigorously for 10 seconds and is maintained on ice for 15 minutes. The homogenate is then transferred to a thick-walled 50 ml polypropylene centrifuge 2 (Fisher Scientific Company, Pittsburgh, PA). The solution is centrifuged at 10,000 x g for 20 minutes at 4C the upper RNA-containing aqueous layer is transferred to a fresh 50 ml polypropylene centrifuge 2 and is mixed with an equal volume of isopropyl alcohol. This solution is maintained at -20C for at least 1 hour to precipitate the RNA. The solution containing the precipitated RNA is centrifuged at 10,000 x g for 20 minutes at 4C. The pelleted total cellular RNA is collected and is dissolved in 3 ml of the denaturing solution described above.

Three ml of the isopropyl alcohol is added to the resuspended total cellular RNA and is vigorously mixed.

This solution is maintained at -20C for at least 1 hour to precipitate the RNA. The solution containing the precipitated RNA is centrifuged at 10,000 x g for 10 minutes at 4C. The pelleted RNA is washed once with a solution containing 75% ethanol. The pelleted RNA is dried under vacuum for 15 minutes and then is re-suspended in dimethyl pyrocarbonate treated (DEPC-H₂O) H₂O.

The messenger RNA (mRNA) prepared above is enriched for sequences containing long poly A tracks as described in Molecular Cloning: A Laboratory Manual, Second Edition, Sambrook et al., eds., Cold Spring Harbor, NY (1989). Briefly, one half of the total RNA isolated from the hybridoma cells is resuspended in 1 ml of DEPC-H₂O and is maintained at 65C for 5 minutes. One ml of 2x high salt loading buffer consisting of 100 mM Tris-HCl, 1 M sodium chloride, 2.0 mM disodium ethylene diamine tetra acetic acid (EDTA) at pH 7.5, and 0.2% sodium dodecyl sulphate (SDS) is added to the resuspended RNA and the mixture is allowed to cool to room temperature. The mixture is then applied to an oligo-dT (Collaborative Research Type 2 or Type 3) column that is previously prepared by washing the oligo-dT with a solution containing 0.1 M sodium hydroxide and 5 mM EDTA and is then equilibrated in DEPC-H₂O. The column eluate is collected in a sterile polypropylene tube and is reappplied to the same column after heating the eluate for 5 minutes at 65C. The oligo-dT column is then washed with 2 ml of high salt loading buffer consisting of 50 mM Tris-HCl at pH 7.5, 500 mM sodium chloride, 1 mM EDTA at pH 7.5 and 0.1% SDS. The oligo-dT column is then washed with 2 ml of 1 x medium salt buffer consisting of 50 mM Tris-HCl at pH 7.5, 100 mM sodium chloride, 1 mM EDTA and 0.1% SDS. The messenger RNA is eluded from the oligo-dT column with 1 ml of buffer consisting of 10 mM Tris-HCl at pH 7.5, 1 mM EDTA at pH 7.5 and 0.05% SDS. The messenger RNA is

purified by extracting this solution with a phenol/
chloroform solution followed by a single extraction with
100% chloroform. The messenger RNA is concentrated by
ethanol precipitation and then resuspended in DEPC-H₂O and
stored at -70C until used.

The messenger RNA isolated by the above process
contains messenger RNA coding for both the heavy and light
chain variable regions that make up the antibody produced
by the hybridoma.

B. Isolation of the Variable Regions Using the
Polymerase Chain Reaction

In preparation for PCR amplification, the
mRNA prepared according to the above examples is used as a
template for cDNA synthesis by a primer extension
reaction. In a typical 50 µl transcription reaction, 5-10
µg of the hybridoma mRNA in water is first hybridized
(annealed) with 500 ng (50.0 pmol) of a 3' V_H primer as
described by Orlandi et al., Proc. Natl. Acad. Sci., USA,
86:3833-3937 (1989) at 65C for 5 minutes. Subsequently
the mixture is adjusted to 1.5 mM dATP, dCTP and dTTP, 40
mM Tris-HCl at pH 8.0, 8 mM MgCl₂, 50 mM NaCl, and 2 mM
spermidine. Moloney-Murine Leukemia Virus reverse
transcriptase (26 units, Stratagene) is added to the
solution and the solution is maintained for 1 hour at 37C.

PCR amplification is performed in a 100 µl
reaction containing the products of the reverse
transcription reaction (approximately 5 µg of the cDNA/RNA
hybrid), 300 ng of the 3' V_H primer described by Orlandi
et al., Proc. Natl. Acad. Sci., USA, 86:3833-3937 (1989).
300 ng each of the eight 5' V_H primers also described by
Orlandi et al., supra, 200 mM of a mixture of dNTP's, 50
mM KCl, 10 mM Tris-HCl pH 8.3, 15 mM MgCl₂, 0.1% gelatin
and 2 units of Taq DNA polymerase. The reaction mixture
is overlaid with mineral oil and subjected to 40 cycles of

amplification. Each amplification cycle involves a denaturation at 92C for 1 minute, annealing at 52C for 2 minutes and polynucleotide synthesis by primer extension (elongation) at 72C for 1.5 minutes. The amplified V_H-coding DNA homolog containing samples are extracted twice with phenol-chloroform, once with chloroform, ethanol precipitated and are stored at -70C and 10 mM Tris-HCl (pH 7.5) and 1 mM EDTA.

The light chain variable region is isolated in a similar fashion except that a 3' V_L primer and a 5' V_L primer specific for either the lambda or kappa light chain was used. The PCR amplification conditions were identical to those described for the heavy chain variable region isolation.

C. Insertion Of The Pathogen Specific Heavy And Light Chain Variable Region Into A Plant Expression Vector

The pathogen specific heavy and light chain variable regions are isolated as described above and are inserted into a plant expression vector containing the constant region of IgA. This vector is constructed using standard molecular biology techniques and is a derivative of pMON 530 that has both the immunoglobulin signal sequence from the 6D4 antibody as described in Example 1 and the immunoglobulin alpha constant region isolated from MOPC 315 that has been fully sequenced and previously described by Auffray et al., Gene, 13:365-374 (1981). This vector also contains a polylinker region position between the immunoglobulin signal sequence and the IgA constant region gene to allow the pathogen specific heavy chain variable region to be easily inserted. The restriction endonuclease sites present in the polylinker are compatible with the restriction endonuclease sites present in the PCR primers used to isolate the heavy chain

variable region. The pathogen specific heavy chain variable region is inserted into the vector by cutting the vector with the appropriate restriction enzymes and also cutting the pathogen specific variable region with the appropriate restriction enzymes sites that are present in the PCR primers used to isolate the variable. The pathogen specific variable region is then ligated into the vector.

This vector is then introduced into a plant using the methods described in Example 4. Plants containing the pathogen specific IgA heavy chain are identified and then crossed with plants containing the pathogen specific light chain.

Plants containing the pathogen specific light chain variable region coupled to an appropriate light chain are produced using similar techniques as the pathogen specific heavy chain variable region containing plants.

A sexual cross is used to place the pathogen specific heavy and light chains in the same plant to produce a plant containing an assembled IgA.

Plants containing the secretory component of IgA are produced by introducing the gene coding for the secretory component into a plant expression vector such as the pMON 530 vector. The sequence of the secretory component has been described by Mostov et al., Nature, 308:37 (1984). The secretory component gene is inserted into the pMON 530 vector together with an appropriate signal sequence using standard molecular biology techniques. The resulting secretory component-containing vector is used to transform plant cells and produce plants containing and expressing the secretory component.

Plants containing the J or joining chain of IgA immunoglobulin are produced by inserting the gene coding for the J chain into a plant expression vector as

described for the secretory component, the light chain and heavy chain. The J chain gene has been sequenced by Max et al., J. Exp. Med., 161:832-849 (1985). In addition, the sequence of other J chains is available in Sequences of Proteins of Immunological Interest, 4th edition, U.S. Dept. of Health and Human Services, (1987). This vector is used to produce plants expressing the J chain.

These J chain expression plants are crossed with the plants expressing the secretory component to produce plants expressing both secretory component and J chain. These plants are then crossed with the plants expressing the pathogen-specific IgA antibody to produce plants expressing true secretory IgA that is made up of two IgA molecules, secretory component and J chain.

D. Production Of Passive Immunity To A Selected Pathogen

Plants producing secretory IgA were produced according to Example 11. These plants produced secretory IgA that was immunospecific for a Shigella toxin. This secretory IgA was produced by isolating the heavy and light chain variable regions from the hybridoma designated 13 C2 (ATCC #CRL1794). Plants expressing the secretory IgA contained approximately 1 mg of secretory IgA for each 10 to 100 grams of plant material. These plants are harvested and used to produce passive immunity while the plant is still fresh.

Adults in which passive immunity is desired are immunized by ingesting 10 to 100 grams of plants expressing the secretory IgA, 1 to 4 times per day. This immunoglobulin ingestion is carried out for a total of 3 days and then the production of passive immunity is analyzed by ingesting a dose of bacteria containing Shigella toxin. The adults ingest approximately 1.2×10^9 colony-forming units of the Shigella bacteria suspended in

1 ounce of water containing sodium bicarbonate. Approximately 15 minutes to 1/2 hour later the adults ingest 10 to 100 grams more of plant containing the secretory IgA.

5 The adults are monitored for the presence of diarrhea for 1 to 2 days after ingesting the bacteria. The occurrence of diarrhea is greatly reduced in the adults ingesting the plant containing the secretory IgA as compared to other adults who did not ingest the secretory
10 IgA-containing plant but were subjected to the same bacterial challenge.

Plants containing a secretory IgA immunospecific for Shigella toxin and Shigella-like toxin (SLT1) are prepared by isolating the heavy and light chain variable
15 regions from the hybridoma 13C2 (ATCC #CRL 1794). The plants contain approximately 1 mg of anti-Shigella antibody per 10 to 100 grams of plant material. Plants containing the anti-Shigella antibody are isolated and homogenized and placed in an infant formula.

20 Infants are given the equivalent of 6-600 mg of antibody present in the required amount of plant material daily in 3 or more doses as a supplement to their normal feeding. These infants are then followed to determine the incidence of Shigella disease in the infants after normal
25 exposure to Shigella bacteria. Infants receiving the plant material containing the secretory IgA specific for Shigella toxin have a greatly reduced incidence of disease caused by Shigella when compared to infants exposed to the same amount of Shigella that did not receive the plant
30 material containing the secretory IgA.

The foregoing is intended as illustrative of the present invention but not limiting. Numerous variations and modifications can be effected without departing from the true spirit and scope of the invention.

WHAT IS CLAIMED IS:

1. A biologically active glycopolypeptide multimer comprising at least two polypeptides, one of said polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a core portion and N-acetylglucosamine-containing outer branches, said multimer being free from sialic acid residues.

2. The biologically active glycopolypeptide multimer of claim 1, wherein said amino acid residue sequence includes an immunoglobulin heavy chain variable region amino acid residue sequence.

3. The biologically active glycopolypeptide multimer of claim 1, wherein said amino acid residue sequence includes an immunoglobulin light chain variable region amino acid residue sequence.

4. The biologically active glycopolypeptide multimer of claim 1, further comprising another polypeptide including another amino acid residue sequence bonded to said polypeptide.

5. The biologically active glycopolypeptide multimer of claim 1, having therewithin at least one catalytic site.

6. The biologically active glycopolypeptide multimer of claim 1, having therewithin at least one enzymatic site.

7. The biologically active glycopolypeptide multimer of claim 1, wherein said amino acid residue sequence defines a catalytic site.

8. A biologically active glycopolypeptide multimer comprising a polypeptide having a glycosylated core portion as well as N-acetylglucosamine-containing outer branches and an immunoglobulin molecule amino acid residue sequence, bonded to another polypeptide including

a different immunoglobulin molecule amino acid residue sequence, said multimer being free from detectable sialic acid.

5 9. The biologically active glycopolypeptide multimer of claim 8, wherein said immunoglobulin molecule amino acid residue sequence includes an immunoglobulin heavy chain variable region amino acid residue sequence.

10 10. The biologically active glycopolypeptide multimer of claim 8, wherein said different immunoglobulin molecule amino acid residue sequence includes an immunoglobulin light chain variable region amino acid residue sequence.

15 11. The biologically active glycopolypeptide multimer of claim 8, wherein said immunoglobulin molecule amino acid residue sequence includes an immunoglobulin heavy chain variable region amino acid residue sequence and said different immunoglobulin molecule amino acid residue sequence includes an immunoglobulin light chain variable region amino acid residue sequence.

20 12. The biologically active glycopolypeptide multimer of claim 8, wherein said immunoglobulin amino acid residue sequence defines a first portion of a catalytic site and said different immunoglobulin molecule amino acid residue sequence defines a second portion of said catalytic site, whereby said first and second portions are associated together to form a greater portion of said catalytic site.

30 13. The biologically active glycopolypeptide multimer of claim 8, wherein said immunoglobulin molecule amino acid residue sequence includes an amino acid residue sequence of an immunoglobulin heavy chain variable region defining a portion of a catalytic site.

35 14. The biologically active glycopolypeptide multimer of claim 8, wherein said different immunoglobulin molecule amino acid residue sequence includes the amino

acid residue sequence of an immunoglobulin light chain variable region defining a portion of a catalytic site.

15. The biologically active complex glycopolyptide multimer of claim 8, wherein said
5 immunoglobulin molecule amino acid residue sequence includes an immunoglobulin heavy chain variable region amino acid residue sequence defining a first portion of a catalytic site and said different immunoglobulin molecule amino acid residue sequence includes an immunoglobulin
10 light chain variable region amino acid residue sequence defining a second portion of a catalytic site, whereby said first and second portions of said catalytic site are associated together to form a greater portion of said catalytic site.

15 16. A biologically active glycopolyptide multimer comprising:

(i) a polypeptide having an oligosaccharide defined by a glycosylated core portion with
20 immunoglobulin molecule amino acid residue sequence, wherein said polypeptide does not bind to a mouse immunoglobulin-binding lectin; and

(ii) another polypeptide containing a different immunoglobulin molecule amino acid residue
25 sequence, wherein said another polypeptide is bonded to said polypeptide.

17. The biologically active glycopolyptide multimer of claim 16, wherein said immunoglobulin molecule amino acid residue sequence includes an immunoglobulin
30 heavy chain variable region amino acid residue sequence.

18. The biologically active glycopolyptide multimer of claim 16, wherein said different immunoglobulin molecule amino acid residue sequence includes an immunoglobulin light chain variable region
35 amino acid residue sequence.

19. The biologically active glycopolyp ptide multimer of claim 16, wherein said mouse immunoglobulin binding lectin is wheat germ agglutinin.

5 20. The biologically active glycopolypeptide multimer of claim 16, wherein said mouse immunoglobulin binding lectin is Ricinus communis agglutinin.

10 21. A method of passively immunizing an animal against a preselected ligand comprising contacting a prophylactic amount of a composition comprising a biologically active glycopolypeptide multimer that is capable of binding a preselected ligand with a mucosal surface of said animal; said multimer comprising a polypeptide having a glycosylated core portion as well as N-acetylglycosamine containing outer branches and an amino acid residue sequence of an immunoglobulin molecule, said multimer being free from detectable sialic acid residues.

15 22. A method for providing passive immunity against a preselected ligand to an animal, which method comprises administering to said animal an encapsulated, biologically active glycopolypeptide multimer capable of binding a preselected ligand in an amount sufficient to establish within said animal a prophylactic concentration thereof; said multimer comprising a polypeptide having a glycosylated core portion as well as N-acetylglycosamine containing outer branches and an amino acid residue sequence of an immunoglobulin molecule, said multimer being free from detectable sialic acid residues.

20 23. A method for providing passive immunity against a pathogen to an animal, which method comprises administering to said animal an encapsulated, biologically active glycopolypeptide multimer capable of binding a pathogen antigen in an amount sufficient to establish within said animal a prophylactic concentration thereof; said multimer comprising a polypeptide having a glycosylated core portion as well as N-ac tylglucosamin -

25 30 35

containing outer branches and an amino acid residue sequence of an immunoglobulin molecule, said multimer being free from detectable sialic acid residues.

5 24. The method of claim 22, wherein said multimer is encapsulated in a plant cell wall.

25. The method of claim 22, wherein said multimer encapsulated in a plant cell and a composition comprising said plant cells is administered.

10 26. The method of claim 22, wherein said multimer is encapsulated in an enteric coating.

27. A method for providing passive immunity against a preselected ligand to an animal, which method comprises administering to said animal a biologically active glycopolypeptide multimer capable of binding a
15 preselected ligand in an amount sufficient to establish within said animal a prophylactic concentration thereof; said multimer comprising a polypeptide having a glycosylated core portion as well as N-acetylglycosamine-containing outer branches and an amino acid residue
20 sequence of an immunoglobulin molecule, said multimer being free from detectable sialic acid residues.

28. A method for providing passive immunity against a pathogen to an animal, which method comprises administering to said animal a biologically active
25 glycopolypeptide multimer capable of binding a pathogen in an amount sufficient to establish within said animal a prophylactic concentration thereof; said multimer comprising a polypeptide having a glycosylated core portion as well as N-acetylglucosamine-containing outer
30 branches and an amino acid residue sequence of an immunoglobulin molecule, said multimer being free from detectable sialic acid residues.

29. The method of claim 27, wherein said multimer is administered as a composition constituted by said
35 multimer and a material having nutritional value.

30. The method of claim 29, wherein said material having nutriti nal value is plant material.

31. The method of claim 29, wherein said material having nutritional value is animal material.

5 32. The method of claim 27, wherein said multimer is administered as a composition constituted by said multimer and a physiologically inert material.

33. The composition of claim 21, wherein said composition further comprises plant material.

10 34. The method of claim 21, wherein said biologically active glycopolypeptide is an IgA molecule.

35. The method of claim 21, wherein said biologically active glycopolypeptide is secretory IgA.

15 36. The method of claim 21, wherein said biologically active glycopolypeptide contains an IgA constant region amino acid residue sequence.

37. The method of claim 21, wherein said preselected ligand is a mucosal pathogen antigen.

20 38. The method of claim 21, wherein said preselected ligand is an intestinal pathogen antigen.

39. The method of claim 38, wherein said intestinal pathogen antigen is an Escherichia coli antigen.

25 40. The method of claim 38, wherein said intestinal pathogen antigen is a Salmonellae antigen.

41. The method of claim 38, wherein said intestinal pathogen antigen is a Vibrio cholerae antigen.

30 42. The method of claim 38, wherein said intestinal pathogen antigen is a Salmonellae typhimurium antigen.

43. The method of claim 21, wherein said preselected ligand is a dental pathogen antigen.

44. The method of claim 43, wherein said dental pathogen antigen is a Streptococcus mutans antigen.

45. The method of claim 21, wherein said animal is a vertebrate.

46. The method of claim 21, wherein said animal is a mammal.

5 47. The method of claim 21, wherein said animal is a fish.

48. The method of claim 21, wherein said animal is a bird.

10 49. The method of claim 21, wherein said animal is a ruminant.

50. The method of claim 21, wherein said animal is a weaned mammal.

51. The method of claim 21, wherein said animal is an adult mammal.

15 52. A method of passively immunizing an animal against a preselected ligand comprising introducing into the gastrointestinal tract of an animal a composition comprising plant cell walls and a biologically active glycopolypeptide multimer that is capable of binding a
20 preselected ligand; said multimer comprises at least two polypeptides, one of said polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a core portion and N-acetylglucosamine-containing outer branches, said multimer
25 being free from sialic acid residues.

53. A method of passively immunizing an animal against a preselected ligand, which method comprises:

(a) introducing into the gastrointestinal tract of an animal a composition comprising plant cells
30 containing a biologically active glycopolypeptide multimer that is capable of binding a preselected ligand; said multimer comprising at least two polypeptides, one of said polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a
35 core portion and N-acetylglucosamine-containing outer

branches, said multimer being free from sialic acid residues; and

(b) disrupting said plant cell within said gastrointestinal tract, thereby releasing said
5 biologically active glycopolypeptide multimer into said gastrointestinal tract, and passively immunizing said animal.

54. A biologically active composition which comprises an encapsulated glycopolypeptide multimer
10 comprising at least two polypeptides, one of said polypeptides having (a) an immunoglobulin amino acid residue sequence, and (b) an oligosaccharide comprising a core portion and a N-acetylglucosamine-containing outer
branches, said multimer being free from sialic acid
15 residues.

55. The composition of claim 54, wherein said coating is a plant cell.

56. The composition of claim 54, wherein said coating is an enteric coating.

57. A glycopolypeptide multimer produced
20 according to the method comprising:

(a) introducing into the genome of a first member of the plant species a first mammalian gene coding for an autogenously linking monomeric polypeptide having a
25 N-linked glycosylation signal that is a constituent part of said glycopolypeptide multimer to produce a first transformant;

(b) introducing into the genome of a second member of the same plant species another mammalian gene coding for another autogenously linking monomeric
30 polypeptide that is a constituent part of said glycopolypeptide multimer to produce a second transformant;

(c) generating from said first and second
35 transformants a progeny population; and

(d) isolating from said progeny population a transgenic plant species that produces said glycopolypeptide multimer.

5 58. The method of claim 30, wherein said plant material is present in a ratio of greater than 1 milligram of plant material for each 1 milligram of glycopolypeptide multimer present.

10 59. The method of claim 30, wherein said plant material is present in a ratio of less than 1 milligram of plant material for each 1 milligram of glycopolypeptide

60. A transgenic plant comprising plant cells that contain plural autogenously linking polypeptide coding mammalian genes; and

15 at least two autogenously linking polypeptides encoded by said genes;

 said autogenously linking polypeptides being associated with one another as a biologically active polypeptide multimer.

20 61. The plant in accordance with claim 60 wherein the multimer is a homomultimer.

62. The plant in accordance with claim 60 wherein the multimer is a heteromultimer.

25 63. The plant in accordance with claim 60 wherein said biologically active polypeptide multimer is an enzyme.

64. The plant in accordance with claim 60 wherein said biologically active polypeptide multimer is a receptor capable of specifically binding a predetermined ligand.

30 65. The plant in accordance with claim 60 wherein said biologically active polypeptide multimer forms an antibody combining site.

35 66. The plant in accordance with claim 60 wherein said biologically active polypeptide multimer is an abzyme.

67. The plant in accordance with claim 60 which is a dicotyl donous plant.

68. The plant in accordance with claim 60 which is a monocotyledonous plant.

5 69. The plant in accordance with claim 60 which is a lower plant.

70. A method for making a transgenic plant capable of producing a biologically active multimeric protein which comprises:

10 (a) introducing into the genome of a first member of the plant species a first gene coding for an immunologically active immunoglobulin heavy chain portion-containing polypeptide to produce a first transformant;

15 (b) introducing into the genome of a second member of the same plant species another gene coding for a polypeptide other than said immunoglobulin heavy chain portion-containing polypeptide but is autogenously linkable therewith, to produce a second transformant;

20 (c) generating from said first and second transformants a progeny population; and

(d) isolating from said progeny population a transgenic plant species producing a heterodimer that includes the immunoglobulin heavy chain portion-containing polypeptide.

25 71. The method in accordance with claim 70 wherein said another gene codes for an immunologically active immunoglobulin light chain portion-containing polypeptide, and wherein isolated from said progeny population is the plant species that produces a
30 heterodimer constituted by the immunoglobulin heavy chain portion-containing polypeptide and the immunoglobulin light chain portion-containing polypeptide.

35 72. The method in accordance with claim 70 wherein said first gene codes for the immunoglobulin heavy chain, wherein said other gene codes for the

immunoglobulin light chain, and wherein isolated from said progeny population is the plant species that produces the corresponding Fab fragment.

73. The method in accordance with claim 70 wherein said first gene codes for the immunoglobulin heavy chain variable region, wherein said other gene codes for the immunoglobulin light chain variable region, and wherein isolated from said progeny population is the plant species that produces the corresponding Fv fragment.

74. A method for producing a heterodimeric antibody which comprises:

(a) cultivating a transgenic plant having plant cells that contain plural polypeptide-coding mammalian genes of which at least one gene codes for an immunologically active immunoglobulin portion-containing polypeptide and another gene codes for a polypeptide autogenously linkable therewith;

(b) harvesting said transgenic plant; and

(c) recovering from the harvested plant said heterodimeric antibody.

75. The method in accordance with claim 74 wherein said recovering step includes (i) homogenizing at least a portion of the harvested plant to a pulp and (ii) extracting the heterodimeric antibody from said pulp.

76. A method of separating a metallic ion from a fluid sample containing said ion, which method comprises the steps of:

(a) admixing said fluid sample with a chelating agent for said metallic ion to form a chelating admixture;

(b) maintaining said chelating admixture for a time period sufficient for said ion to bind said chelating agent and form a metallic ion chelation complex containing composition;

(c) contacting plant cells that contain therewithin a heterodimeric antibody specific to said

metallic ion chelation complex with said composition to form a binding admixture;

5 (d) maintaining said binding admixture for a time period sufficient for said metallic ion chelation complex to enter said plant cells and form a reaction product with said heterodimeric antibody within said plant cells; and

(e) removing said reaction product containing plant cells from said binding admixture.

10 77. The method of claim 76 wherein said plant cells constitute a viable plant.

78. A transgenic plant with an elevated metallic ion concentration produced by the method comprised of:

15 (a) admixing a metallic ion-containing fluid sample with a chelating agent for said metallic ion to form a chelating admixture;

(b) maintaining said chelating admixture for a time period sufficient for said metallic ion to bind said chelating agent and form a metallic ion chelation complex;

20 (c) commingling said metallic ion chelation complex with plant cells that contain therewithin a heterodimeric antibody specific to said metallic ion chelation complex to form a binding admixture; and

25 (d) maintaining said binding admixture for a time period sufficient for said metallic ion chelation complex to enter said plant cells and form a reaction product with said heterodimeric antibody within said plant cells.

30 79. A transgenic plant containing an immunoreaction complex comprised of a metallic ion chelation complex and a heterodimeric antibody capable of specifically binding the metallic ion chelation complex.




FIG. IA




FIG. IB




FIG. 2

3 / 12






FIG. 3

4 / 12



5 / 12





FIG. 5

SUBSTITUTE SHEET

6 / 12


FIG. 6A



COMPLEX

7 / 12


FIG. 6 B




HYBRID

8./ 12

FIG. 6C



HIGH MANNOSE



NAME	GROUP SUBSTITUTED	SUBSTITUTION GROUP	TYPICAL SOURCE
N-ACETYLNEURAMINIC ACID	C (5)	CH ₃ CONH-	COMMON
N-GLYCOLYLNEURAMINIC ACID	C (5)	HOCH ₂ CONH	PIG TISSUES > 90%
O-ACETYL DERIVATIVES	C (9)	CH ₃ CO-	BOVINE SUBMANDIBULAR GLAND (RARE)
	C (7)	CH ₃ CO-	
	C (4)	CH ₃ CO-	HORSE TISSUE

FIG. 7

10 / 12




FIG. 8

SUBSTITUTE SHEET




FIG. 9B




FIG. 9A

SUBSTITUTE SHEET

12 / 12




FIG.10

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): A61K 39/395; C07K 15/14

U.S. CL.: 424/85.8; 530/387

II. FIELDS SEARCHEDMinimum Documentation Searched ⁷

Classification System	Classification Symbols
U.S.	424/85.8, 88; 435/69.1, 252.3, 320; 530/387, 388, 389; 935/29, 35, 56, 60, 67

Documentation Searched other than Minimum Documentation
to the extent that such documents are included in the fields searched ⁸

DATABASES: DIALOG (FILES 5, 72, 172, 155, 351, 399, 10); USPTO Automated Patent System (File USPAT, 1971-1991).

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	NATURE, Vol 321, issued 1986. Thorens. et al., "Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion." pages 618-620. see Abstract, abstract No. 6216213.	1-2.4
Y	SCIENCE, Vol. 227, issued 08 March 1985. Horsch, et al., "A Simple and General Method for Transferring Genes into Plants." pages 1229-1231. see entire document.	1-2.4.33
Y	SCIENCE, Vol. 236, issued 05 June 1987. Cocking, et al., "Gene Transfer in Cereals." pages 1259-1262. see entire document.	1-2.4.33
Y	WO, A, 87/00865 (Goodman, et al.) 12 February 1987. See entire document.	1-2.4.33

¹⁰ Special categories of cited documents:¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance¹⁰ "E" earlier document but published on or after the international filing date¹⁰ "L" document which may throw doubts on priority claims) or which is cited to establish the publication date of another citation or other special reason (as specified)¹⁰ "O" document referring to an oral disclosure, use, exhibition or other means¹⁰ "P" document published prior to the international filing date but later than the priority date claimed¹¹ "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention¹¹ "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step¹¹ "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art¹¹ "S" document member of the same patent family**IV. CERTIFICATION**

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

15 March 1991

18 APR 1991

International Searching Authority

Signature of Authorizing Officer

ISA/US

Robert D. Budens

III. D DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
P.Y	US. A. 4,956,282 (Goodman et al.) 11 September 1990. See entire document, particularly column 3.	1-2,4,33
P.Y	NATURE. Vol. 342. issued 02 November 1989. Hiatt et al., "Production of Antibodies in transgenic plants." pages 76-78. See entire document.	
P.Y	JOURNAL of EXPERIMENTAL MEDICINE. Vol. 167. issued February 1988. Aizpurua et al., "Oral Vaccination: Identification of Classes of Proteins that Provoke an Immune Response upon Oral Feeding." pages 440-451. See Results and Discussion.	23

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter ^{1,2} not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out ^{1,2}, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

See attached sheets

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers: 1-2,4,21 and 33

Telephonic practice

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.